WO2001097860A2 - Produits pharmaceutiques pour l'imagerie de troubles angiogeniques - Google Patents

Produits pharmaceutiques pour l'imagerie de troubles angiogeniques Download PDF

Info

Publication number
WO2001097860A2
WO2001097860A2 PCT/US2001/020108 US0120108W WO0197860A2 WO 2001097860 A2 WO2001097860 A2 WO 2001097860A2 US 0120108 W US0120108 W US 0120108W WO 0197860 A2 WO0197860 A2 WO 0197860A2
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
group
independently selected
acid
gly
Prior art date
Application number
PCT/US2001/020108
Other languages
English (en)
Other versions
WO2001097860A3 (fr
Inventor
Milind Rajopadhye
D. Scott Edwards
John A. Barrett
Alan P. Carpenter, Jr.
Stuart J. Heminway
Shuang Liu
Prahlad Singh
Original Assignee
Bristol-Myers Squibb Pharma Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Pharma Company filed Critical Bristol-Myers Squibb Pharma Company
Priority to AU2001268710A priority Critical patent/AU2001268710A1/en
Priority to EP01946697A priority patent/EP1311302A2/fr
Priority to JP2002503343A priority patent/JP2005538030A/ja
Priority to CA002413328A priority patent/CA2413328A1/fr
Publication of WO2001097860A2 publication Critical patent/WO2001097860A2/fr
Publication of WO2001097860A3 publication Critical patent/WO2001097860A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/082—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being a RGD-containing peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A61K51/1251—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles micro- or nanospheres, micro- or nanobeads, micro- or nanocapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Definitions

  • the present invention provides novel pharmaceuticals useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient.
  • the invention is also directed to novel pharmaceutical compositions and combination therapy comprising a compound of the invention or a pharmaceutically acceptable salt thereof, and at least one agent selected from the group consisting of an anti-cancer agent, a photosensitizer agent and a radiosensitizer agent.
  • the present invention also provides novel pharmaceuticals useful for monitoring therapeutic angiogenesis treatment and destruction of new angiogenic vasculature.
  • the pharmaceuticals are comprised of a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a therapeutically effective radioisotope or diagnostically effective imageable moiety.
  • the therapeutically effective radioisotope emits a particle or electron sufficient to be cytotoxic.
  • the imageable moiety is a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
  • Cancer is a major public health concern in the United States and around the world. It is estimated that over 1 million new cases of invasive cancer will be diagnosed in the United States in 1998. The most prevalent forms of the disease are solid tumors of the lung, breast, prostate, colon and rectum. Cancer is typically diagnosed by a combination of in vitro tests and imaging procedures .
  • the imaging procedures include X-ray computed tomography, magnetic resonance imaging, ultrasound imaging and radionuclide scintigraphy.
  • a contrast agent is administered to the patient to enhance the image obtained by X-ray CT, MRI and ultrasound, and the administration of a radiopharmaceutical that localizes in tumors is required for radionuclide scintigraphy.
  • Treatment of cancer typically involves the use of external beam radiation therapy and chemotherapy, either alone or in combination, depending on the type and extent of the disease.
  • a number of anti-cancer agents are available, but generally they all suffer from a lack of specificity for tumors versus normal tissues, resulting in considerable side-effects.
  • the effectiveness of these treatment modalities is also limited, as evidenced by the high mortality rates for a number of cancer types, especially the more prevalent solid tumor diseases. More effective and specific treatment means continue to be needed.
  • metallopharmaceutical that localizes specifically in the tumor by binding to a receptor expressed only in tumors or expressed to a significantly greater extent in tumors than in other tissue.
  • the location of the metallopharmaceutical could then be detected externally either by its imageable emission in the case of certain radiopharmaceuticals or by its effect on the relaxation rate of water in the immediate vicinity in the case of magnetic resonance imaging contrast agents.
  • This tumor specific metallopharmaceutical approach can also be used for the treatment of cancer when the metallopharmaceutical is comprised of a particle emitting radioisotope.
  • the radioactive decay of the isotope at the site of the tumor results in sufficient ionizing radiation to be toxic to the tumor cells .
  • the specificity of this approach for tumors minimizes the amount of normal tissue that is exposed to the cytotoxic agent and thus may provide more effective treatment with fewer side-effects .
  • radionuclide labeled monoclonal antibodies, antibody fragments and other proteins or polypeptides that bind to tumor cell surface receptors .
  • the specificity of these radiopharmaceuticals is frequently very high, but they suffer from several disadvantages.
  • Angiogenesis is the process by which new blood vessels are formed from pre-existing capillaries or post capillary venules; it is an important component of a variety of physiological processes including ovulation, embryonic development, wound repair, and collateral vascular generation in the myocardium. It is also central to a number of pathological conditions such as tumor growth and metastasis, diabetic retinopathy, and macular degeneration.
  • the process begins with the activation of existing vascular endothelial cells in response to a variety of cytokines and growth factors . Tumor released cytokines or angiogenic factors stimulate vascular endothelial cells by interacting with specific cell surface receptors for the factors.
  • the activated endothelial cells secrete enzymes that degrade the basement membrane of the vessels.
  • the endothelial cells then proliferate and invade into the tumor tissue.
  • the endothelial cells differentiate to form lumens, making new vessel offshoots of pre-existing vessels.
  • the new blood vessels then provide nutrients to the tumor permitting further growth and a route for metastasis.
  • endothelial cell proliferation is a very slow process, but it increases for a short period of time during embryogenesis, ovulation and wound healing. This temporary increase in cell turnover is governed by a combination of a number of growth stimulatory factors and growth suppressing factors. In pathological angiogenesis, this normal balance is disrupted resulting in continued increased endothelial cell proliferation.
  • pro- angiogenic factors include basic fibroblast growth factor (bFGF) , angiogenin, TGF- alpha, TGF-beta, and vascular endothelium growth factor (VEGF) , while interferon-alpha, interferon-beta and thrombospondin are examples of angiogenesis suppressors.
  • bFGF basic fibroblast growth factor
  • angiogenin angiogenin
  • TGF- alpha TGF-beta
  • VEGF vascular endothelium growth factor
  • interferon-alpha, interferon-beta and thrombospondin are examples of angiogenesis suppressors.
  • Integrins are a diverse family of heterodimeric cell surface receptors by which endothelial cells attach to the extracellular matrix, each other and other cells.
  • the integrin 0 ⁇ 3 is a receptor for a wide variety of extracellular matrix proteins with an exposed tripeptide Arg-Gly-Asp moiety and mediates cellular adhesion to its ligands: vitronectin, fibronectin, and fibrinogen, among others .
  • the integrin ⁇ v ⁇ 3 is minimally expressed on normal blood vessels, but, is significantly upregulated on vascular cells within a variety of human tumors.
  • the role of the ⁇ 3 receptors is to mediate the interaction of the endothelial cells and the extracellular matrix and facilitate the migration of the cells in the direction of the angiogenic signal, the tumor cell population.
  • Angiogenesis induced by bFGF or TNF-alpha depend on the agency of the integrin 0 ⁇ 3
  • angiogenesis induced by VEGF depends on the integrin Ov ⁇ s (Cheresh et. al . , Science, 1995, 270, 1500-2).
  • Induction of expression of the integrins Xi ⁇ i and O ⁇ i on the endothelial cell surface is another important mechanism by which VEGF promotes angiogenesis (Senger, et. al . , Proc. Natl. Acad, Sci USA, 1997, 94, 13612-7) .
  • Angiogenic factors interact with endothelial cell surface receptors such as the receptor tyrosine kinases EGFR, FGFR, PDGFR, Flk-1/KDR, Flt-1, Tek, Tie, neuropilin-1, endoglin, endosialin, and Axl .
  • the receptors Flk-1/KDR, neuropilin-1, and Flt-1 recognize VEGF and these interactions play key roles in VEGF- induced angiogenesis .
  • the Tie subfamily of receptor tyrosine kinases are also expressed prominently during blood vessel formation.
  • angiostatin is a 38 kDa fragment of plasminogen that has been shown in animal models to be a potent inhibitor of endothelial cell proliferation.
  • Endostatin is a 20 kDa C-terminal fragment of collagen XVIII that has also been shown to be a potent inhibitor.
  • Another approach to anti-angiogenic therapy is to use targeting moieties that interact with endothelial cell surface receptors expressed in the angiogenic vasculature to which are attached anti-cancer agents.
  • Burrows and Thorpe (Proc. Nat. Acad. Sci, USA, 1993, 90, 8996-9000) described the use of an antibody-immunotoxin conjugate to eradicate tumors in a mouse model by destroying the tumor vasculature .
  • the antibody was raised against an endothelial cell class II antigen of the major histocompatibility complex and was then conjugated with the cytotoxic agent, deglycosylated ricin A chain. The same group (Clin. Can.
  • angiogenesis-targeted therapeutic radiopharmaceuticals and an anti-cancer agents or a radiosensitizer agent, or a pharmaceutically acceptable salt thereof, which target the luminal side of the neovasculature of tumors, to provide a surprising, and enhanced degree of tumor suppression relative to each treatment modality alone without significant additive toxicity.
  • Photodynamic therapy has also been used in the treatment of cancer. Photodynamic therapy involves the administration of a photosensitive agent and subsequent irradiation with light to excite the photosensitizer, thus producing a cytotoxic effect. Spears, U.S. Pat. No. 4,512,762, and U.S. Pat. No. 4,566,636, Kelly, et al . United States Patent 6,235,767.
  • the photosensitizers used are capable of localizing in malignant cells, either by natural tendency or because they have been intentionally targeted to a specific type of tissue, or both. When irradiated, they may be capable of fluorescing and, thus, may also be useful in diagnostic methods related to detecting target tissue.
  • the photosensitizer has the capacity, when irradiated with light at a wavelength which the compound absorbs, of causing a cytotoxic effect against whatever cells or other tissue in which the photosensitizer has localized.
  • a photosensitizer agent having a characteristic light absorption waveband is first administered to the patient, typically either orally or by injection.
  • Abnormal tissue in the body is known to selectively absorb certain photosensitizer agents to a much greater extent than normal tissue. More effective selectivity can be achieved using a photoreactive agent that is bound to an antibody, which links with antigens on targeted cells. The cancerous or abnormal tissue that has absorbed or linked with the photosensitizer dye is then destroyed by administering light of an appropriate wavelength or waveband corresponding to the absorption wavelength or waveband of the photosensitizer agent.
  • Photosensitizing agents such as Photofrin, a haematoporphyrin derivative, are known.
  • Photosensitizers therapy and detection of malignant tumours. Photochem. Photobiol . , 45, 879-889, and Boyle R. W. and D. David (1996) Structure and biodistribution relationships of photodynamic sensitizers. Photochem. Photobiol. 64, 469-485)
  • Rodgers,et al . United States Patent No.
  • 6,225,333 discloses treating cancers with a variety of photosensitizing agents for example naphthalocyanine photosensitizing agents; tetrapyrrole-based photosensitizers; including porphyins; chlorins;, phthalocyanines; napthalocyanines ; coumarins and psoralens. Furthermore, Mazur, et al . , United States Patent No.
  • 6,229,0408 discloses a method for treatment of solid tumors by photodynamic therapy comprising administering a photosensitizer selected from the group consisting • of : 1,3,4, 6-tetrahydroxyhelianthrone; 1,3,4, 6-tetramethoxyhelianthrone; 10, 13-dimethyl- 1, 3 , 4, 6-tetrahydroxyhelianthrone; 10,13- di (methoxycarbonyl) -1,3,4, 6-tetramethoxyhelianthrone; 1, 6-di-N-butylamino-3 , 4-dimethoxy-helianthrone; 1, 6-di- N-butylamino-3 , 4-dimethoxy-10 , 13-dimethyl-helianthrone; 1, 6-di- (N-hydroxyethylamino) -3 , 4-dimethoxy-helianthrone; 2 , 5-dibromo-l, 3 , 4, 6-tetrahydroxyhelianthrone; and 2,5- dibromo
  • green porphyrins have been used in photodynamic therapy with light having a wavelength range around 670-780 nm. See for example, Levy et al . , U.S. Pat. No. 5,399,583 Levy et al . , U.S. Pat. No. 4,920,143, Levy et al . , U.S. Pat. No. 5,095,030; and Levy et al . , and U.S. Pat. No. 5,171,749.
  • a method must be found for the irradiating light to reach the targeted tissue where the photosensitizer has been localized.
  • a light-emitting balloon catheter may be used or alternatively, a form of "liquid light” may be injected into the vascular tree such that the "liquid light”, perfuses the vasculature at the target site. Spears, U.S. Pat. No. 4,512,762. Alternatively,
  • the targeted tissues are visually located by imaging the treatment site through a fiber optic system so that light from a laser source can be accurately directed through the optical fiber to destroy the abnormal tissue. Even when the internal treatment site is accessible through natural body orifices, an endoscope is usually required to visualize the targeted tissue and accurately direct the light therapy administered to the treatment site.
  • Chen, United States Patent No. 6,210,425 discloses an apparatus and a method to identify an internal treatment site within a patient's body for administration of light therapy and treatment of the site.
  • a photosensitizer agent as part of photodynamic therapy
  • an angiogenesis-targeted therapeutic radiopharmaceutical and an anti-cancer agent or a radiosensitizer agent, or a pharmaceutically acceptable salt thereof, which target the luminal side of the neovasculature of tumors, to provide a surprising, and enhanced degree of tumor suppression relative to each treatment modality alone without significant additive toxicity.
  • the receptor binding compounds target the radioisotope to the tumor neovasculature.
  • the beta or alpha-particle emitting radioisotope emits a cytotoxic amount of ionizing radiation which results in cell death.
  • the penetrating ability of radiation obviates the requirement that the cytotoxic agent diffuse or be transported into the cell to be cytotoxic .
  • These pharmaceuticals comprise a targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and a radioisotope that emits cytotoxic radiation (i.e., beta particles, alpha particles and Auger or Coster-Kronig electrons) .
  • cytotoxic radiation i.e., beta particles, alpha particles and Auger or Coster-Kronig electrons
  • the radiopharmaceuticals of the present invention that emit cytotoxic radiation could be used to destroy the new angiogenic vasculature that results and thus treat the disease.
  • kits and therapeutic radiopharmacutical compositions for use in combination therapy comprising a radiopharmacutical of the invention and at least one agents selected from the group consisting of an anticancer agent and a radiosensitizer agent.
  • kits and therapeutic radiopharmacutical compositions for use in combination therapy comprising a radiopharmacutical of the invention and a photosensitising agent.
  • tumor imaging agents comprised of targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and an imageable moiety, such as a gamma ray or positron emitting radioisotope, a magnetic resonance imaging contrast agent, an X-ray contrast agent, or an ultrasound contrast agent.
  • Imaging agents for monitoring the progress and results of therapeutic angiogenesis treatment.
  • These agents comprise of targeting moiety that binds to a receptor that is upregulated during angiogenesis, an optional linking group, and an imageable moiety.
  • Imaging agents of the present invention could be administered intravenously periodically after the administration of growth factors and imaging would be performed using standard techniques of the affected areas, heart or limbs, to monitor the progress and results of the therapeutic angiogenesis treatment (i.e., image the formation of new blood vessels) .
  • the compounds may have one or more protecting groups attached to the metal chelator or bonding moiety.
  • the protecting groups provide improved stability to the reagents for long-term storage and are removed either immediately prior to or concurrent with the synthesis of the radiopharmaceuticals.
  • the compounds of the present invention are comprised of a peptide or peptidomimetic targeting moiety that binds to a receptor that is upregulated during angiogenesis, Q, an optional linking group, L n , and a surfactant, S f .
  • the pharmaceuticals of the present invention may be used for diagnostic and/or therapeutic purposes.
  • Diagnostic radiopharmaceuticals of the present invention are pharmaceuticals comprised of a diagnostically useful radionuclide (i.e., a radioactive metal ion that has imageable gamma ray or positron emissions) .
  • Therapeutic radiopharmaceuticals of the present invention are pharmaceuticals comprised of a therapeutically useful radionuclide, a radioactive metal ion that emits ionizing radiation such as beta particles, alpha particles and Auger or Coster-Kronig electrons .
  • the pharmaceuticals comprising a gamma ray or positron emitting radioactive metal ion are useful for imaging tumors by gamma scintigraphy or positron emission tomography.
  • the pharmaceuticals comprising a gamma ray or positron emitting radioactive metal ion are also useful for imaging therapeutic angiogenesis by gamma scintigraphy or positron emission tomography.
  • the pharmaceuticals comprising a particle emitting radioactive metal ion are useful for treating cancer by delivering a cytotoxic dose of radiation to the tumors.
  • the pharmaceuticals comprising a particle emitting radioactive metal ion are also useful for treating rheumatoid arthritis by destroying the formation of angiogenic vasculature.
  • the pharmaceuticals comprising a paramagnetic metal ion are useful as magnetic resonance imaging contrast agents.
  • the pharmaceuticals comprising one or more X-ray absorbing or "heavy" atoms of atomic number 20 or greater are useful as X-ray contrast agents.
  • the pharmaceuticals comprising a microbubble of a biocompatible gas, a liquid carrier, and a surfactant microsphere, are useful as ultrasound contrast agents.
  • the present invention provides a kit for treating cancer, comprising a compound of the formula (I) and at least one agent selected from the group consisting of an anti-cancer agent and a radiosensitizer agent, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, wherein the compound of the formula (I) is:
  • Q is a peptide independently selected from the group :
  • K is an L-amino acid independently selected at each occurrence from the group: arginine, citrulline, N-methylarginine , lysine, homolysine, 2-aminoethylcysteine , ⁇ -N-2-imidazolinylornithine , 6-N-benzylcarbamoylornithine, and ⁇ -2-benzimidazolylacetyl-l, 2-diaminopropionic acid;
  • K' is a D-amino acid independently selected at each occurrence from the group: arginine, citrulline, N-methylarginine, lysine, homolysine, 2-aminoethylcysteine, ⁇ -N-2-imidazolinylornithine, ⁇ -N-benzylcarbamoylornithine, and ⁇ -2-benzimidazolylacetyl-l, 2-diaminopropionic acid;
  • L is independently selected at each occurrence from the group: glycine, L-alanine, and D-alanine;
  • M is L-aspartic acid
  • M' is D-aspartic acid
  • R 1 is an amino acid substituted with 0-1 bonds to L n , independently selected at each occurrence from the group: glycine, L-valine, D-valine, alanine, leucine, isoleucine, norleucine, 2-aminobutyric acid, 2-aminohexanoic acid, tyrosine, phenylalanine, thienylalanine, phenylglycine, cyclohexylalanine, homophenylalanine, 1-naphthylalanine,. lysine, serine, ornithine,
  • R 2 is an amino acid, substituted with 0-1 bonds to L n , independently selected at each occurrence from the group: glycine, valine, alanine, leucine, isoleucine, norleucine, 2-aminobutyric acid, 2-aminohexanoic acid, tyrosine, L-phenylalanine, D- phenylalanine, thienylalanine, phenylglycine, biphenylglycine, cyclohexylalanine, homophenylalanine, L-1-naphthylalanine, D-1-naphthylalanine, lysine, serine, ornithine, 1, 2-diaminobutyric acid, 1, 2-diaminopropionic acid, cysteine, penicillamine, methionine, and 2-aminothiazole-4-acetic acid; R 3 is an amino acid, substituted with 0-1 bonds to L n ,
  • R 4 is an amino acid, substituted with 0-1 bonds to L n , independently selected at each occurrence from the group: glycine, D-valine, D-alanine, D-leucine, D-isoleucine, D-norleucine, D-2-aminobutyric acid, D-2-aminohexanoic acid, D-tyrosine,
  • R 5 is an amino acid, substituted with 0-1 bonds to L n , independently selected at each occurrence from the group: glycine, L-valine, L-alanine, L-leucine, L-isoleucine, L-norleucine, L-2-aminobutyric acid, L-2-aminohexanoic acid, L-tyrosine,
  • R 1 , R 2 , R , R 4 , and R 5 in each Q is substituted with a bond to L n , further provided that when R 2 is 2-aminothiazole-4-acetic acid, K is N-methylarginine, further provided that when R 4 is 2-aminothiazole-4-acetic acid, K and K' are N-methylarginine, and still further provided that when R 5 is 2-aminothiazole-4-acetic acid, K' is N-methylarginine;
  • d is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
  • L n is a linking group having the formula:
  • aa is independently at each occurrence an amino acid
  • Z is selected from the group: aryl substituted with 0-3 R 10 , C 3 _ ⁇ o cycloalkyl substituted with 0-3 R 10 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 10 ;
  • R 10 is independently selected at each occurrence from the group: a bond to C h , COOR 11 , OH, NHR 11 , SO 3 H, PO 3 H, aryl substituted with 0-3 R 11 , C ⁇ _ 5 alkyl substituted with 0-1 R 12 , C ⁇ _ 5 alkoxy substituted with 0-1 R 12 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 1 ;
  • R 11 is independently selected at each occurrence from the group: H, aryl substituted with 0-1 R 12 , a
  • R 12 is a bond to C h ;
  • k is selected from 0, 1, and 2; h is selected from 0, 1, and 2; h' is selected from 0, 1, 2, 3, 4, and 5; h" is selected from 0, 1, 2, 3, 4, and 5; g is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; g' is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and
  • g is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and
  • C h is a metal bonding unit having a formula selected from the group:
  • a 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , and A 8 are independently selected at each occurrence from the group N, NR 13 , NR 13 R 14 , S, SH, S(Pg), 0, OH, PR 13 , PR 1 R 14 , P(0)R 15 R 16 , and a bond to L n;
  • E is a bond, CH, or a spacer group independently selected at each occurrence from the group: C ⁇ C ⁇ o alkyl substituted with 0-3 Ri 7 , aryl substituted with 0-3 R l7 , C 3 _ ⁇ o cycloalkyl substituted with 0-3 R ⁇ , heterocyclo-C ⁇ _ ⁇ o alkyl substituted with 0-3 R! , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0, Ce-io aryl-Ci-io alkyl substituted with 0-3 R 7 , Ci-io alkyl-C 6 - ⁇ o aryl- substituted with 0-3 R! , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R 17 ,-
  • R 13 , and R 4 are each independently selected from the group: a bond to L n , hydrogen, Ci-Cio alkyl substituted with 0-3 R ⁇ 7 , aryl substituted with 0-3 R 7 , C]__ ⁇ o cycloalkyl substituted with 0-3 R l , heterocyclo-C ⁇ _ ⁇ o alkyl substituted with 0-3 R ⁇ 7 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0, Cg-io aryl-C ⁇ _ ⁇ o alkyl substituted with 0-3 R 17 , C ⁇ _ ⁇ o alkyl-C 6 - ⁇ o aryl- substituted with 0-3 R!
  • R 15 and R 16 are each independently selected from the group: a bond to L n , -OH, C1-C10 alkyl substituted with 0-3 R 17 , Ci-Cio alkyl substituted with 0-3
  • R 1 aryl substituted with 0-3 R 17 , C 3 _ ⁇ o cycloalkyl substituted with 0-3 R 17 , heterocyclo-C ⁇ _ o alkyl substituted with 0-3 R 17 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0, C 6 _ ⁇ o aryl-C ⁇ _ ⁇ o alkyl substituted with 0-3 R 17 , C ⁇ _ ⁇ o alkyl-C 6 _ ⁇ o aryl- substituted with 0-3 R 1 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R l7 ;
  • R 18 , R 1 a , and R 9 are independently selected at each occurrence from the group: a bond to L n , H, C1-C6 alkyl, phenyl, benzyl, Ci-C ⁇ alkoxy, halide, nitro, cyano, and trifluoromethyl ;
  • Pg is a thiol protecting group
  • R 20 and R 21 taken together with the divalent carbon radical to which they are attached form:
  • R 22 and R 23 are independently selected from the group : H, R 24 , C1-C10 alkyl substituted with 0-3 R 24 , C2-C10 alkenyl substituted with 0-3 R 24 , C2-C10 alkynyl substituted with 0-3 R 24 , aryl substituted with 0-3 R 24 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 24 , and C 3 _ ⁇ o carbocycle substituted with 0-3 R 24 ;
  • R 22 , R 23 taken together form a fused aromatic or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0;
  • a and b indicate the positions of optional double bonds and n is 0 or 1;
  • R 25 , R 25a , and R 26 are each independently selected at each occurrence from the group: hydrogen and C1-C6 alkyl ;
  • the present invention provides a kit according to Embodiment 1 wherein:
  • L is glycine
  • R 1 is an amino acid, optionally substituted with a bond to L n , independently selected at each occurrence from the group: L-valine, D-valine, alanine, leucine, isoleucine, norleucine, 2-aminobutyric acid, tyrosine, phenylalanine, phenylglycine, cyclohexylalanine, homophenylalanine, lysine, ornithine, 1, 2-diaminobutyric acid, and 1, 2-diaminopropionic acid;
  • R 2 is an amino acid, optionally substituted with a bond to L n , independently selected at each occurrence from the group: valine, alanine, leucine, isoleucine, norleucine, 2-aminobutyric acid, tyrosine, L-phenylalanine, D-phenylalanine, thienylalanine, phenylglycine, biphenylglycine
  • R 3 is an amino acid, optionally substituted with a bond to L n , independently selected at each occurrence from the group: D-valine, D-alanine, D-leucine,
  • R 4 is an amino acid, optionally substituted with a bond to L n , independently selected at each occurrence from the group: D-valine, D-alanine, D-leucine, D-isoleucine, D-norleucine, D-2-aminobutyric acid, D-tyrosine, D-phenylalanine, D-thienylalanine, D-phenylglycine, D-cyclohexylalanine , D-homophenylalanine, D-1-naphthylalanine, D-lysine, D-ornithine, D-l, 2-diaminobutyric acid, D-l, 2-diaminopropionic acid, and 2-aminothiazole-4-acetic acid;
  • R 5 is an amino acid, optionally substituted with a bond to L n , independently selected at each occurrence from the group: L-valine, L-alanine, L-leucine, L-isoleucine, L-norleucine, L-2-aminobutyric acid, L-tyrosine, L-phenylalanine, L-thienylalanine, L-phenylglycine, L-cyclohexylalanine, L-homophenylalanine, L-1-naphthylalanine, L-lysine, L-ornithine, L-l, 2-diaminobutyric acid, L-l, 2-diaminopropionic acid, and 2-aminothiazole-4-acetic acid;
  • d is selected from 1, 2, and 3;
  • Z is selected from the group: aryl substituted with 0-1 R 10 , C 3 - 10 cycloalkyl substituted with 0-1 R 10 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-1 R 10 ;
  • R 10 is independently selected at each occurrence from the group: COOR 11 , OH, NHR 11 , S0 3 H, aryl substituted with 0-1 R 11 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-1 R 11 , C 1 -C 5 alkyl substituted with 0-1 R 12 , C 1 -C 5 alkoxy substituted with 0-1 R 12 , and a bond to C ;
  • R 11 is independently selected at each occurrence from the group: H, aryl substituted with 0-1 R 12 , a
  • heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-1 R 12 , polyalkylene glycol substituted with 0-1 R 12 , carbohydrate substituted with 0-1 R 12 , cyclodextrin substituted with 0-1 R 12 , amino acid substituted with 0-1 R 12 , and a bond to C h ;
  • a 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , and A 8 are independently selected at each occurrence from the group: NR 13 , NR 13 R 14 , S, SH, S(Pg), OH, and a bond to L n ;
  • E is a bond, CH, or a spacer group independently selected at each occurrence from the group: C -C10 alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 17 , C 3 _ ⁇ o cycloalkyl substituted with 0-3 R "7 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 ;
  • R 13 , and R 1 ⁇ are each independently selected from the group: a bond to L n , hydrogen, C1-C10 alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 1 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 1 , and an electron, provided that when one of R 13 or R 1 ⁇ is an electron, then the other is also an electron;
  • R 18 , R 1 8a / and R 19 are independently selected at each occurrence from the group: a bond to L n , H, and C1-C6 alkyl;
  • R 20 and R 21 are independently selected from the group: H, C1-C5 alkyl, -CO2R 25 , C 2 -C 5 1-alkene substituted with 0-3 R 23 , C 2 -C 5 1-alkyne substituted with 0-3 R 23 , aryl substituted with 0-3 R 23 , and unsaturated 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 23 ;
  • R 20 and R 21 taken together with the divalent carbon radical to which they are attached form:
  • R 22 and R 23 are independently selected from the group: H, and R 24 ;
  • R 22 , R 23 taken together form a fused aromatic or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0;
  • R 25 is independently selected at each occurrence from the group: H and C1-C3 alkyl.
  • the present invention provides a kit according to Embodiment 1 wherein: Q is a peptide selected from the group:
  • R 1 is L-valine, D-valine, D-lysine optionally substituted on the ⁇ amino group with a bond to L n or L-lysine optionally substituted on the ⁇ amino group with a bond to L n ;
  • R 2 is L-phenylalanine, D-phenylalanine,
  • R 3 is D-valine, D-phenylalanine, or L-lysine optionally substituted on the ⁇ amino group with a bond to L n ;
  • R 4 is D-phenylalanine, D-tyrosine substituted on the hydroxy group with a bond to L n , or L-lysine optionally substituted on the ⁇ amino group with a bond to L n ;
  • R 2 is 2-aminothiazole-4-acetic acid, K is N-methylarginine ;
  • d is 1 or 2;
  • a 1 is selected from the group: OH, and a bond to L n ;
  • a 2 , A 4 , and A 6 are each N;
  • a 3 , A 5 , and A 8 are each OH;
  • a 7 is a bond to L n or NH-bond to L n ;
  • E is a C2 alkyl substituted with 0-1 R 17 ;
  • a 2 is NHR 13 ;
  • R 13 is a heterocycle substituted with R 17 , the heterocycle being selected from pyridine and pyrimidine;
  • R 18 is a bond to L n ;
  • R 24 is selected from the group: -C0 2 R 25 , -OR 25 , -SO 3 H, and -N(R 25 ) 2 ;
  • R 25 is independently selected at each occurrence from the group : hydrogen and methyl;
  • a 1 , A 2 , A 3 , and A 4 are each N;
  • a 5 , A 6 , and A 8 are each OH;
  • a 7 is a bond to L n ;
  • E is a C2 alkyl substituted with 0-1 R 17 ;
  • the present invention provides a kit according to Embodiment 1 wherein a compound of the formula (I) is selected from the group consisting of: (a) cyclo ⁇ Arg-Gly-Asp-D-Tyr(N-[2-[ [ [5- [carbonyl] -2- pyridinyl]hydrazono] methyl] -benzenesulfonic acid] - 3-aminopropyl) -Val ⁇ ; (b) cyclo ⁇ Arg-Gly-Asp-D-Tyr ( (N- [2- [ [ [5- [carbonyl] -2- pyridinyl] hydrazono] methyl] -benzenesulfonic acid] - 18-amino-14-aza-4, 7, 10-oxy-15-oxo-octadecoyl) -3- aminopropyl) -Val ⁇ ;
  • the present invention provides a kit according to Embodiment 1, wherein the kit further comprises one or more ancillary ligands and a reducing agent .
  • the present invention provides a kit according to Embodiment 5, wherein the ancillary ligands are tricine and TPPTS .
  • the present invention provides a kit according to Embodiment 5, wherein the reducing agent is tin (II).
  • the present invention provides a kit according to Embodiment 1, wherein the anti-cancer agent is selected from the group consisting of mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine, bicalutamide, vinorelbine, vesnarinone, aminoglutethimide, amsacrine
  • the present invention provides a kit according to Embodiment 1, wherein the anti-cancer agent is selected from the group consisting of mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine, bicalutamide, vinorelbine, vesnarinone, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, is
  • the present invention provides a kit according to Embodiment 1 wherein the anti-cancer agent is selected from the group consisting of oxymetholone, tamoxifen, progesterone, mepitiostane, epitiostanol, and formestane.
  • the anti-cancer agent is selected from the group consisting of oxymetholone, tamoxifen, progesterone, mepitiostane, epitiostanol, and formestane.
  • the present invention provides a kit according to Embodiment 1 wherein the anti-cancer agent is selected from the group consisting of interferon-alpha, interferon-2 alpha, interferon- beta, interferon-gamma, colony stimulating factor-1, colony stimulating factor-2, denileukin diftitox, interleukin-2, and leutinizing hormone releasing factor.
  • the anti-cancer agent is selected from the group consisting of interferon-alpha, interferon-2 alpha, interferon- beta, interferon-gamma, colony stimulating factor-1, colony stimulating factor-2, denileukin diftitox, interleukin-2, and leutinizing hormone releasing factor.
  • the present invention provides a kit according to Embodiment 1, wherein radiosensitizer agent is selected from the group consiting of 2- (3-nitro-l, 2 , 4-triazol-l-yl) -N- (2- methoxyethyl) acetamide, N- (3-nitro-4-quinolinyl) -4- morpholinecarboxamidine, 3-amino-l, 2 , 4-benzotriazine-
  • radiosensitizer agent is selected from the group consiting of 2- (3-nitro-l, 2 , 4-triazol-l-yl) -N- (2- methoxyethyl) acetamide, N- (3-nitro-4-quinolinyl) -4- morpholinecarboxamidine, 3-amino-l, 2 , 4-benzotriazine-
  • the present invention provides a therapeutic radiopharmaceutical composition
  • a therapeutic radiopharmaceutical composition comprising at least one agent selected from the group consisting of an anti-cancer agent and a radiosensitizer agent, or a pharmaceutically acceptable salt thereof, and a radiopharmaceutical comprising: a) a radioisotope; b) a chelator capable of chelating the radioisotope; and c) a targeting moiety; wherein the targeting moiety is bound to the chelator through 0-1 linking groups, and the targeting moiety is a peptide or peptidomimetic that binds to a receptor that is upregulated during angiogenesis.
  • the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 13 , wherein the targeting moiety is a cyclic pentapeptide and the receptor is 0Cv ⁇ 3 •
  • the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 14 , wherein the radiopharmaceutical comprises: a) a radioisotope selected from the group 33 125j # 186 Re , 188 Re , 153 Sm/ 166 Ho , 177 Lu , 149 Pltl 90 ⁇ , 212 Bi , 1 03 Pd , 109 Pd , 159 Gd/ 140 La , 198 AU/ 199 Au , 169 ⁇ b
  • K is an L-amino acid independently selected at each occurrence from- the group: arginine, citrulline, N-methylarginine, lysine, homolysine, 2-aminoethylcysteine, ⁇ -N-2-imidazolinylornithine, ⁇ -N-benzylcarbamoylornithine, and ⁇ -2-benzimidazolylacetyl-l , 2-diaminopropionic acid;
  • K' is a D-amino acid independently selected at each occurrence from the group: arginine, citrulline, N-methylarginine, lysine, homolysine,
  • L is independently selected at each occurrence from the group: glycine, L-alanine, and D-alanine;
  • M is L-aspartic acid
  • M' is D-aspartic acid
  • R 1 is an amino acid substituted with 0-1 bonds to L n , independently selected at each occurrence from the group: glycine, L-valine, D-valine, alanine, leucine, isoleucine, norleucine, 2-aminobutyric acid, 2-aminohexanoic acid, tyrosine, phenylalanine, thienylalanine, phenylglycine, cyclohexylalanine, homophenylalanine, 1-naphthylalanine, lysine, serine, ornithine, 1, 2-diaminobutyric acid, 1, 2-diaminopropionic acid, cysteine, penicillamine, and methionine;
  • R 2 is an amino acid, substituted with 0-1 bonds to L n , independently selected at each occurrence from the group: glycine, valine, alanine, leucine, isoleucine, norleucine, 2-aminobutyric acid, 2-aminohexanoic acid, tyrosine, L-phenylalanine, D- phenylalanine, thienylalanine, phenylglycine, biphenylglycine , cyclohexylalanine, homophenylalanine, L-1-naphthylalanine, D-1-naphthylalanine, lysine, serine, ornithine, 1, 2-diaminobutyric acid, 1, 2-diaminopropionic acid, cysteine, penicillamine, methionine, and 2-aminothiazole-4-acetic acid;
  • R 3 is an amino acid, substituted with 0-1 bonds to L n , independently selected at each occurrence from the group: glycine, D-valine, D-alanine, D-leucine, D-isoleucine, D-norleucine, D-2-aminobutyric acid, D-2-aminohexanoic acid, D-tyrosine,
  • R 4 is an amino acid, substituted with 0-1 bonds to L n , independently selected at each occurrence from the group: glycine, D-valine, D-alanine, D-leucine,
  • R 5 is an amino acid, substituted with 0-1 bonds to L n , independently selected at each occurrence from the group: glycine, L-valine, L-alanine, L-leucine, L-isoleucine, L-norleucine, L-2-aminobutyric acid, L-2-aminohexanoic acid, L-tyrosine,
  • R 1 , R 2 , R 3 , R 4 , and R 5 in each Q is substituted with a bond to L n , further provided that when R 2 is 2-aminothiazole-4-acetic acid, K is N-methylarginine, further provided that when R 4 is 2-aminothiazole-4-acetic acid, K and K' are N-methylarginine, and still further provided that when R 5 is 2-aminothiazole-4-acetic acid, K' is N-methylarginine ;
  • d is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
  • L n is a linking group having the formula:
  • aa is independently at each occurrence an amino acid
  • Z is selected from the group: aryl substituted with 0-3 R 10 , C 3 _ o cycloalkyl substituted with 0-3 R 10 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 10 ;
  • R 10 is independently selected at each occurrence from the group: a bond to C h , COOR 11 , OH, NHR 11 , SO 3 H, PO 3 H, aryl substituted with 0-3 R 11 , C ⁇ _ 5 alkyl substituted with 0-1 R 12 , C ⁇ _ 5 alkoxy substituted with 0-1 R 12 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 1 ;
  • R 11 is independently selected at each occurrence from the group: H, aryl substituted with 0-1 R 12 , a
  • R 12 is a bond to C h ;
  • k is selected from 0, 1, and 2; h is selected from 0, 1, and 2; h' is selected from 0, 1, 2, 3, 4, and 5; h" is selected from 0, 1, 2, 3, 4, and 5; g is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; g' is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; g" is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and
  • C h is a metal bonding unit having a formula selected from the group:
  • a 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , and A 8 are independently selected at each occurrence from the group N, NR 13 , NR 13 R 14 , S, SH, S(Pg), 0, OH, PR 13 , PR 13 R 14 , P(0)R 15 R 16 , and a bond to L n ,-
  • E is a bond, CH, or a spacer group independently selected at each occurrence from the group: Ci-Cio alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 17 , C 3 _ ⁇ o cycloalkyl substituted with 0-3 R 17 , heterocyclo-C ⁇ _ ⁇ o alkyl substituted with 0-3 R 17 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0, C 6 -io aryl-C ⁇ _ ⁇ o alkyl substituted with 0-3 R 17 , Cl-10 alkyl-C6- ⁇ o aryl- substituted with 0-3 R 17 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 ;
  • R 13 , and R 1 ⁇ are each independently selected from the group: a bond to L n , hydrogen, Ci-Cio alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 17 , C ⁇ _ ⁇ o cycloalkyl substituted with 0-3 R 17 , heterocyclo-C ⁇ _ ⁇ o alkyl substituted with 0-3 R 17 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0, C 6 - ⁇ o aryl-Ci- o alkyl substituted with 0-3 R 17 , C ⁇ _ ⁇ o alkyl-Cg-io aryl- substituted with 0-3 R 17 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 , and an electron, provided that when one of R 13 or R 1 ⁇ is an
  • R 15 and R 16 are each independently selected from the group: a bond to L n , -OH, Ci-Cio alkyl substituted with 0-3 R 17 , Ci-Cio alkyl substituted with 0-3
  • R 7 aryl substituted with 0-3 R 17 , C 3 _ ⁇ o cycloalkyl substituted with 0-3 R 17 , heterocyclo-C ⁇ _ ⁇ o alkyl substituted with 0-3 R 17 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O, C 6 _ ⁇ o aryl-Ci-io alkyl substituted with 0-3 R 17 , Ci-io alkyl-C 6 _ ⁇ o aryl- substituted with 0-3 R 7 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 ;
  • R 18 , R 18a , and R 19 are independently selected at each occurrence from the group: a bond to L n , H, Ci-Cg alkyl, phenyl, benzyl, Ci-C ⁇ alkoxy, halide, nitro, cyano, and trifluoromethyl ;
  • Pg is a thiol protecting group
  • R 20 and R 21 taken together with the divalent carbon radical to which they are attached form:
  • R 22 and R 23 are independently selected from the group: H, R 24 , Ci-Cio alkyl substituted with 0-3 R 24 , C2 _ ClO alkenyl substituted with 0-3 R 24 , C2-C10 alkynyl substituted with 0-3 R 24 , aryl substituted with 0-3 R 24 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and O and substituted with 0-3 R 24 , and C 3 -- 10 carbocycle substituted with 0-3 R 24 ;
  • R 22 , R 23 taken together form a fused aromatic or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0;
  • a and b indicate the positions of optional double bonds and n is 0 or 1;
  • R 25 , R 25a , and R 26 are each independently selected at each occurrence from the group: hydrogen and Ci-C ⁇ alkyl ;
  • the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 15, wherein: L is glycine ;
  • R 1 is an amino acid, optionally substituted with a bond to L n , independently selected at each occurrence from the group: L-valine, D-valine, alanine, leucine, isoleucine, norleucine, 2-aminobutyric acid, tyrosine, phenylalanine, phenylglycine, cyclohexylalanine, homophenylalanine, lysine, ornithine, 1, 2-diaminobutyric acid, and 1, 2-diaminopropionic acid;
  • R 2 is an amino acid, optionally substituted with a bond to L n , independently selected at each occurrence from the group: valine, alanine, leucine, isoleucine, norleucine, 2-aminobutyric acid, tyrosine, L-phenylalanine, D-phenylalanine, thienylalanine, phenylglycine, biphenylglycine, cyclohexylalanine, homophenylalanine , L-1-naphthylalanine, D-1-naphthylalanine, lysine, ornithine, 1, 2-diaminobutyric acid, 1, 2-diaminopropionic acid, and 2-aminothiazole-4-acetic acid;
  • R 3 is an amino acid, optionally substituted with a bond to L n , independently selected at each occurrence from the group: D-valine, D-alanine, D-leucine, D-isoleucine, D-norleucine, D-2-aminobutyric acid, D-tyrosine, D-phenylalanine, D-phenylglycine, D-cyclohexylalanine, D-homophenylalanine, D-lysine, D-serine, D-ornithine, D-l, 2-diaminobutyric acid, and D-l, 2-diaminopropionic acid;
  • R 4 is an amino acid, optionally substituted with a bond to L n , independently selected at each occurrence from the group: D-valine, D-alanine, D-leucine, D-isoleucine, D-norleucine, D-2-aminobutyric acid, D-tyrosine, D-phenylalanine, D-thienylalanine, D-phenylglycine, D-cyclohexylalanine, D-homophenylalanine, D-1-naphthylalanine, D-lysine, D-ornithine, D-l, 2-diaminobutyric acid, D-l, 2-diaminopropionic acid, and 2-aminothiazole-4-acetic acid;
  • R 5 is an amino acid, optionally substituted with a bond to L n , independently selected at each occurrence from the group: L-valine, L-alanine, L-leucine, L-isoleucine, L-norleucine, L-2-aminobutyric acid, L-tyrosine, L-phenylalanine, L-thienylalanine, L-phenylglycine , L-cyclohexylalanine , L-homophenylalanine, L-1-naphthylalanine, L-lysine, L-ornithine, L-l, 2-diaminobutyric acid, L-l, 2-diaminopropionic acid, and 2-aminothiazole-4-acetic acid;
  • d is selected from 1, 2, and 3;
  • Z is selected from the group: aryl substituted with 0-1 R 10 , C 3 _ ⁇ o cycloalkyl substituted with 0-1 R 10 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-1 R 10 ;
  • R 10 is independently selected at each occurrence from the group: COOR 11 , OH, NHR 11 , SO 3 H, aryl substituted with 0-1 R 11 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-1 R 11 , C 1 -C 5 alkyl substituted with 0-1 R 12 , C 1 -C 5 alkoxy substituted with 0-1 R 12 , and a bond to C h ,*
  • R 11 is independently selected at each occurrence from the group: H, aryl substituted with 0-1 R 12 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-1 R 12 , polyalkylene glycol substituted with 0-1 R 12 , carbohydrate substituted with 0-1 R 12 , cyclodextrin substituted with 0-1 R 12 , amino acid substituted with 0-1 R 12 , and a bond to C h ;
  • a 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , and A 8 are independently selected at each occurrence from the group: NR 13 , NR 13 R 14 , S, SH, S(Pg), OH, and a bond to L n ;
  • E is a bond, CH, or a spacer group independently selected at each occurrence from the group: Ci-Cio alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 17 , C 3 - 10 cycloalkyl substituted with 0-3
  • R 17 and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 ;
  • R 13 , and R 1 ⁇ are each independently selected from the group: a bond to L n , hydrogen, C1-C10 alkyl substituted with 0-3 R 1 , aryl substituted with 0-3 R 17 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 , and an electron, provided that when one of R 13 or R! is an electron, then the other is also an electron;
  • R 18 , R 18a , and R 19 are independently selected at each occurrence from the group: a bond to L n , H, and C1-C6 alkyl; R 20 and R 21 are independently selected from the group:
  • R 20 and R 21 taken together with the divalent carbon radical to which they are attached form:
  • R 22 and R 23 are independently selected from the group: H, and R 24 ;
  • R 22 , R 23 taken together form a fused aromatic or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0;
  • R 25 is independently selected at each occurrence from the group: H and C1-C3 alkyl.
  • the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 15, wherein the radioisotope is 153 Sm.
  • the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 17, wherein the radiopharmaceutical is selected from the group: cyclo (Arg-Gly-Asp-D-Phe-Lys (DTPA- 153 Sm) ) ; cyclo (Arg-Gly-Asp-D-Phe-Lys) 2 (DTPA- 153 Sm) ; and, cyclo (Arg-Gly-Asp-D-Tyr (N-DTPA( 153 Sm) -3-aminopropyl) - Val) .
  • the radiopharmaceutical is selected from the group: cyclo (Arg-Gly-Asp-D-Phe-Lys (DTPA- 153 Sm) ) ; cyclo (Arg-Gly-Asp-D-Lys) 2 (DTPA- 153 Sm) ; and, cyclo (Arg-Gly-Asp-D-Tyr (N-DTPA(
  • the present invention provides a therapeutic radiopharmaceutical composition, according to Embodiment 15, wherein the radioisotope is 17 Lu.
  • the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 19, wherein the radiopharmaceutical is selected from the group: cyclo (Arg-Gly-Asp-D-Phe-Lys (DTPA- 177 Lu) ) ; (DOTA- 177 Lu) -Glu(cyclo ⁇ Lys-Arg-Gly-Asp-D-Phe ⁇ ) - cyclo ⁇ Lys-Arg-Gly-Asp-D-Phe ⁇ ; cyclo (Arg-Gly-Asp-D-Phe-Lys) 2 (DTPA- 177 Lu) ; and, cyclo (Arg-Gly-Asp-D-Tyr (N-DTPA( 177 Lu) -3-aminopropyl) - Val) .
  • the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 21, wherein the radiopharmaceutical is :
  • the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 15, wherein the anti-cancer agent is selected from the group consisting of mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine,
  • the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 15, wherein radiosensitizer agent is selected from the group consiting of 2- ⁇ 3- nitro-1, 2 , 4-triazol-l-yl) -N- (2-methoxyethyl) acetamide, N- (3-nitro-4-quinolinyl) -4-morpholinecarboxamidine, 3- amino-1 , 2 , 4-benzotriazine-l, 4-dioxide, N- (2- hydroxyethyl) -2-nitroimidazole-l-acetamide, 1- (2- nitroimidazol-1-yl) -3- (1-piperidinyl) -2-propanol, and 1-
  • the present invention provides a method of treating cancer in a patient comprising: administering to a patient in need thereof a therapeutic radiopharmaceutical comprising: a) a radioisotope; b) a chelator capable of chelating the radioisotope 1; and c) a targeting moiety; wherein the targeting moiety is bound to the chelator through a linking group, and the targeting moiety is a peptide or peptidomimetic that binds to a receptor that is upregulated during angiogenesis, and the radioisotope is a radioisotope selected from the group: 33 ⁇ 125j / 186 Re , 188 Re , 153 Sm/ 166 H ⁇ / 177 LU/ 149pm, 90 Y 212 Bi , !03p d , iOgpd, i5
  • the present invention provides a method according to Embodiment 25, wherein the targeting moiety is a cyclic pentapeptide and the receptor is ⁇ v ⁇ 3 or v ⁇ s • [27] In another embodiment, the present invention provides a method according to Embodiment 25, wherein the therapeutic radiopharmaceutical comprises: a) a radioisotope selected from the group: 33p, 1 25 ⁇ ;
  • K is an L-amino acid independently selected at each occurrence from the group: arginine, citrulline, N-methylarginine, lysine, homolysine, 2-aminoethylcysteine, ⁇ -N-2-imidazolinylornithine , ⁇ -N-benzylcarbamoylornithine, and ⁇ -2-benzimidazolylacetyl-l, 2-diaminopropionic acid;
  • K' is a D-amino acid independently selected at each occurrence from the group: arginine, citrulline, N-methylarginine, lysine, homolysine, 2-aminoethylcysteine, ⁇ -N-2-imidazolinylornithine, ⁇ -N-benzylcarbamoylornithine, and ⁇ -2-benzimidazolylacetyl-l, 2-diaminopropionic acid;
  • L is independently selected at each occurrence from the group: glycine, L-alanine, and D-alanine;
  • M is L-aspartic acid
  • M' is D-aspartic acid
  • R 1 is an amino acid substituted with 0-1 bonds to L n , independently selected at each occurrence from the group: glycine, L-valine, D-valine, alanine, leucine, isoleucine, norleucine, 2-aminobutyric acid, 2-aminohexanoic acid, tyrosine, phenylalanine, thienylalanine, phenylglycine, cyclohexylalanine, homophenylalanine, 1-naphthylalanine, lysine, serine, ornithine, 1, 2-diaminobutyric acid, 1, 2-diaminopropionic acid, cysteine, penicillamine, and methionine;
  • R 2 is an amino acid, substituted with 0-1 bonds to L n , independently selected at each occurrence from the group: glycine, valine, alanine, leucine, isoleucine, norleucine, 2-aminobutyric acid, 2-aminohexanoic acid, tyrosine, L-phenylalanine, D- phenylalanine, thienylalanine, phenylglycine, biphenylglycine, cyclohexylalanine, homophenylalanine, L-1-naphthylalanine,
  • R 3 is an amino acid, substituted with 0-1 bonds to L n , independently selected at each occurrence from the group: glycine, D-valine, D-alanine, D-leucine, D-isoleucine, D-norleucine, D-2-aminobutyric acid, D-2-aminohexanoic acid, D-tyrosine,
  • R 4 is an amino acid, substituted with 0-1 bonds to L n , independently selected at each occurrence from the group: glycine, D-valine, D-alanine, D-leucine, D-isoleucine, D-norleucine, D-2-aminobutyric acid, D-2-aminohexanoic acid, D-tyrosine, D-phenylalanine, D-thienylalanine, D-phenylglycine, D-cyclohexylalanine, D-homophenylalanine, D-1-naphthylalanine, D-lysine, D-serine, D-ornithine, D-l, 2-diaminobutyric acid, D-l, 2-diaminopropionic acid, D-cysteine, D-penicillamine, D-methionine, and 2-aminothiazole-4-acetic acid;
  • R 5 is an amino acid, substituted with 0-1 bonds to L n , independently selected at each occurrence from the group: glycine, L-valine, L-alanine, L-leucine, L-isoleucine, L-norleucine, L-2-aminobutyric acid, L-2-aminohexanoic acid, L-tyrosine,
  • R 1 , R 2 , R 3 , R 4 , and R 5 in each Q is substituted with a bond to L n , further provided that when R 2 is 2-aminothiazole-4-acetic acid, K is N-methylarginine, further provided that when R 4 is 2-aminothiazole-4-acetic acid, K and K' are N-methylarginine, and still further provided that when R 5 is 2-aminothiazole-4-acetic acid, K' is N-methylarginine;
  • d is selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10;
  • L n is a linking group having the formula:
  • aa is independently at each occurrence an amino acid
  • Z is selected from the group: aryl substituted with 0-3 R 10 , C 3 - 10 cycloalkyl substituted with 0-3 R 10 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 10 ;
  • R 10 is independently selected at each occurrence from the group: a bond to C h , COOR 11 , OH, NHR 11 , SO 3 H, PO 3 H, aryl substituted with 0-3 R 11 , C ⁇ _ 5 alkyl substituted with 0-1
  • R 11 is independently selected at each occurrence from the group: H, aryl substituted with 0-1 R 12 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-1 R 12 , C 3 _ ⁇ o cycloalkyl substituted with 0-1 R 12 , polyalkylene glycol substituted with 0-1 R 12 , carbohydrate substituted with 0-1 R 12 , cyclodextrin substituted with 0-1 R 12 , amino acid substituted with 0-1 R 12 , polycarboxyalkyl substituted with 0-1 R 12 , polyazaalkyl substituted with 0-1 R 12 , peptide substituted with 0-1 R 12 , wherein the peptide is comprised of 2-10 amino acids, and a bond to C ;
  • R 12 is a bond to C ;
  • k is selected from 0, 1, and 2; h is selected from 0, 1, and 2 ; h' is selected from 0, 1, 2, 3, 4, and 5; h" is selected from 0, 1, 2, 3, 4, and 5; g is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; g' is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and
  • g is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and
  • g" ' is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and
  • s is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; s' is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; s" is selected from 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, and
  • C h is a metal bonding unit having a formula selected from the group:
  • a 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , and A 8 are independently selected at each occurrence from the group: N, NR 13 , NR 13 R 14 , S, SH, S(Pg), 0, OH, PR 13 , PR 13 R 14 , P(0)R 15 R 16 , and a bond to L n ;
  • E is a bond, CH, or a spacer group independently selected at each occurrence from the group: Ci-Cio alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 17 , C 3 -. 10 cycloalkyl substituted with 0-3 R 17 , heterocyclo-C _ ⁇ o alkyl substituted with 0-3 R 17 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0, C 6 _ ⁇ o aryl-Ci-io alkyl substituted with 0-3 R 17 , C ⁇ _ ⁇ o alkyl-C6-io aryl- substituted with 0-3 R 17 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 ;
  • R 13 , and R 1 ⁇ are each independently selected from the group: a bond to L n , hydrogen, Ci-Cio alkyl substituted with 0-3 R 1 , aryl substituted with 0-3 R 17 , C ⁇ _ ⁇ o cycloalkyl substituted with 0-3 R 1 , heterocyclo-C ⁇ _ o alkyl substituted with 0-3 R 17 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0, C 6 _ ⁇ o aryl-C ⁇ _ ⁇ o alkyl substituted with 0-3 R 1 , C ⁇ _ ⁇ o alkyl-Cs-io aryl- substituted with 0-3 R 17 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 , and an electron, provided that when one of R 13 or R 1 ⁇ is an
  • R 15 and R 16 are each independently selected from the group: a bond to L n , -OH, Ci-Cio alkyl substituted with 0-3 R 1 , Ci-Cio alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 17 , C 3 .- 10 cycloalkyl substituted with 0-3 R 17 , heterocyclo-C - 1 0 alkyl substituted with 0-3 R 17 , wherein the heterocyclo group is a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0, Cg-io aryl-Ci-io alkyl substituted with 0-3 R 17 , C ⁇ _ ⁇ o alkyl-C 6 - ⁇ o aryl- substituted with 0-3 R 7 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17
  • R 18 , R 1 a , and R 19 are independently selected at each occurrence from the group: a bond to L n , H, C1-C6 alkyl, phenyl, benzyl, C1-C6 alkoxy, halide, nitro, cyano, and trifluoromethyl ;
  • Pg is a thiol protecting group
  • R 20 and R 21 taken together with the divalent carbon radical to which they are attached form:
  • R 22 and R 23 are independently selected from the group: H, R 24 , C1-C10 alkyl substituted with 0-3 R 24 , C2 ⁇ C ⁇ o alkenyl substituted with 0-3 R 24 , C2-C10 alkynyl substituted with 0-3 R 24 , aryl substituted with 0-3 R 24 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 24 , and C 3 _ ⁇ o carbocycle substituted with 0-3 R 24 ;
  • R 22 , R 23 taken together form a fused aromatic or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0;
  • a and b indicate the positions of optional double bonds and n is 0 or 1;
  • R 25 , R 25a , and R 26 are each independently selected at each occurrence from the group: hydrogen and C ⁇ -C( alkyl;
  • the present invention provides a method according to. Embodiment 27, wherein:
  • L is glycine
  • R 1 is an amino acid, optionally substituted with a bond to L n , independently selected at each occurrence from the group: L-valine, D-valine, alanine, leucine, isoleucine, norleucine, 2-aminobutyric acid, tyrosine, phenylalanine, phenylglycine, cyclohexylalanine, homophenylalanine, lysine, ornithine, 1, 2-diaminobutyric acid, and 1, 2-diaminopropionic acid;
  • R 2 is an amino acid, optionally substituted with a bond to L n , independently selected at each occurrence from the group: valine, alanine, leucine, isoleucine, norleucine, 2-aminobutyric acid, tyrosine, L-phenylalanine, D-phenylalanine, thienylalanine, phenylglycine, biphenylglycine, cyclohexylalanine, homophenylalanine, L-1-naphthylalanine, D-1-naphthylalanine, lysine, ornithine, 1, 2-diaminobutyric acid, 1, 2-diaminopropionic acid, and 2-aminothiazole-4-acetic acid;
  • R 3 is an amino acid, optionally substituted with a bond to L n , independently selected at each occurrence from the group: D-valine, D-alanine, D-leucine, D-isoleucine, D-norleucine, D-2-aminobutyric acid, D-tyrosine, D-phenylalanine, D-phenylglycine, D-cyclohexylalanine, D-homophenylalanine, D-lysine, D-serine, D-ornithine, D-l, 2-diaminobutyric acid, and D-l, 2-diaminopropionic acid;
  • R 4 is an amino acid, optionally substituted with a bond to L n , independently selected at each occurrence from the group: D-valine, D-alanine, D-leucine,
  • R 5 is an amino acid, optionally substituted with a bond to L n , independently selected at each occurrence from the group: L-valine, L-alanine, L-leucine, L-isoleucine, L-norleucine, L-2-aminobutyric acid, L-tyrosine, L-phenylalanine, L-thienylalanine, L-phenylglycine, L-cyclohexylalanine, L-homophenylalanine, L-1-naphthylalanine, L-lysine, L-ornithine, L-l, 2-diaminobutyric acid, L-l, 2-diaminopropionic acid, and 2-aminothiazole-4-acetic acid;
  • Z is selected from the group: aryl substituted with 0-1 R 10 , C 3 _ ⁇ o cycloalkyl substituted with 0-1 R 10 , and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-1 R 10 ;
  • R 10 is independently selected at each occurrence from the group: COOR 11 , OH, NHR 11 , SO 3 H, aryl substituted with 0-1 R 11 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-1 R 11 , C -C 5 alkyl substituted with 0-1 R 12 , C 1 -C 5 alkoxy substituted with 0-1 R 12 , and a bond to C ;
  • R 11 is independently selected at each occurrence from the group: H, aryl substituted with 0-1 R 12 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-1 R 12 , polyalkylene glycol substituted with 0-1 R 12 , carbohydrate substituted with 0-1 R 12 , cyclodextrin substituted with 0-1 R 12 , amino acid substituted with 0-1 R 12 , and a bond to C h ;
  • a 1 , A 2 , A 3 , A 4 , A 5 , A 6 , A 7 , and A 8 are independently selected at each occurrence from the group : NR 13 , NR 13 R 14 , S, SH, S(Pg), OH, and a bond to L n ;
  • E is a bond, CH, or a spacer group independently selected at each occurrence from the group: Ci-Cio alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 17 , C 3 _ ⁇ o cycloalkyl substituted with 0-3
  • R 17 and a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 ;
  • R 13 , and R 14 are each independently selected from the group: a bond to L n , hydrogen, Ci-Cio alkyl substituted with 0-3 R 17 , aryl substituted with 0-3 R 7 , a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0 and substituted with 0-3 R 17 , and an electron, provided that when one of R 13 or R 4 is an electron, then the other is also an electron;
  • R 18 , R 1 a , and R 19 are independently selected at each occurrence from the group: a bond to L n , H, and C1-C6 alkyl;
  • R 20 and R 21 are independently selected from the group:
  • R 20 and R 21 taken together with the divalent carbon radical to which they are attached form:
  • R 22 and R 23 are independently selected from the group: H, and R 24 ; alternatively, R 22 , R 23 taken together form a fused aromatic or a 5-10 membered heterocyclic ring system containing 1-4 heteroatoms independently selected from N, S, and 0;
  • R 25 is independently selected at each occurrence from the group: H and C1-C3 alkyl.
  • the present invention provides a method according to Embodiment 27, wherein:
  • Q is a peptide selected from the group:
  • R 1 is L-valine, D-valine, D-lysine optionally substituted on the ⁇ amino group with a bond to L n or L-lysine optionally substituted on the ⁇ amino group with a bond to L n ;
  • R 2 is L-phenylalanine, D-phenylalanine,
  • R 3 is D-valine, D-phenylalanine, or L-lysine optionally substituted on the ⁇ amino group with a bond to L n ;
  • R 4 is D-phenylalanine, D-tyrosine substituted on the hydroxy group with a bond to L n , or L-lysine optionally substituted on the ⁇ amino group with a bond to L n ;
  • R 2 is ,2-aminothiazole-4-acetic acid, K is N-methylarginine ;
  • d is 1 or 2;
  • a 1 is selected from the group: OH, and a bond to L n ;
  • a 2 , A 4 , and A 6 are each N;
  • a 3 , A 5 , and A 8 are each OH;
  • a 7 is a bond to L n or NH-bond to L n ;
  • E is a C2 alkyl substituted with 0-1 R 17 ;
  • a 2 is NHR 13 ;
  • R 13 is a heterocycle substituted with R 17 , the heterocycle being selected from pyridine and pyrimidine;
  • R 18 is a bond to L n ;
  • R 24 i s selected from the group: -C0 2 R 25 , -OR 25 , -S0 3 H, and -N(R 25 ) 2 ;
  • R 25 is independently selected at each occurrence from the group : hydrogen and methyl ;
  • a 1 , A 2 , A 3 , and A 4 are each N;
  • a 5 , A 6 , and A 8 are each OH;
  • a 7 is a bond to L n ;
  • E is a C2 alkyl substituted with 0-1 R 1 ;
  • the present invention provides a method according to Embodiment 27 wherein the compound of formula (I) is selected from the group consisting of:
  • the present invention provides a method according to Embodiment 27, wherein the radioisotope is 153 Sm.
  • the present invention provides a method according to Embodiment 31, wherein the radiopharmaceutical is selected from the group : cyclo (Arg-Gly-Asp-D-Phe-Lys (DTPA- 153 Sm) ) ; cyclo (Arg-Gly-Asp-D-Phe-Lys) 2 (DTPA- 153 Sm) ; and, cyclo (Arg-Gly-Asp-D-Tyr (N-DTPA( 153 Sm) -3-aminopropyl) - Val) .
  • the radiopharmaceutical is selected from the group : cyclo (Arg-Gly-Asp-D-Phe-Lys (DTPA- 153 Sm) ) ; cyclo (Arg-Gly-Asp-D-Lys) 2 (DTPA- 153 Sm) ; and, cyclo (Arg-Gly-Asp-D-Tyr (N-DTPA( 153 Sm
  • the present invention provides a method according to Embodiment 27, wherein the radioisotope is 177 Lu.
  • the present invention provides a method according to Embodiment 27, wherein the radiopharmaceutical is selected from the group: cyclo (Arg-Gly-Asp-D-Phe-Lys (DTPA- 177 Lu) ) ; (DOTA- 177 Lu) -Glu ( cyclo ⁇ Lys-Arg-Gly-Asp-D-Phe ⁇ ) - cyclo ⁇ Lys-Arg-Gly-Asp-D-Phe ⁇ ; cyclo (Arg-Gly-Asp-D-Phe-Lys) 2 (DTPA- 177 Lu) ; and, cyclo (Arg-Gly-Asp-D-Tyr (N-DTPA( 177 Lu) -3-aminopropyl) - Val) .
  • the present invention provides a method according to Embodiment 27, wherein the radioisotope is 90 Y.
  • the present invention provides a method according to Embodiment 25 wherein administering the therapeutic radiopharmaceutical and agent is concurrent.
  • the present invention provides a method according to Embodiment 25 wherein administering the therapeutic radiopharmaceutical and agent is sequential.
  • the present invention provides a method according to Embodiment 25 wherein the cancer is selected from the group consisting of carcinomas of the lung, breast, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, prostate, thyroid, squamous cell carcinomas, adenocarcinomas, small cell carcinomas, melanomas, gliomas, and neuroblastomas .
  • the cancer is selected from the group consisting of carcinomas of the lung, breast, ovary, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, prostate, thyroid, squamous cell carcinomas, adenocarcinomas, small cell carcinomas, me
  • the present invention provides a method according to Embodiment 25 wherein the anti-cancer agent is selected from the group consisting of mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzoxane, nedaplatin, cytarabine, bicalutamide, vinorelbine, vesnarinone, aminoglutethimide, amsacrine, proglumide, elliptinium acetate, ketanserin, doxifluridine, etretinate, is
  • the present invention provides a method according to Embodiment 25 wherein the radiosensitizer agent is selected from the group consisting of 2- (3-nitro-l, 2 , 4-triazol-l-yl) -N- (2- methoxyethyl) acetamide, N- (3-nitro-4-quinolinyl) -4- morpholinecarboxamidine, 3-amino-l, 2 , 4-benzotriazine- 1,4-dioxide, N- (2-hydroxyethyl) -2-nitroimidazole-l- acetamide, 1- (2-nitroimidazol-l-yl) -3- (1-piperidinyl) - 2-propanol, and 1- (2-nitro-l-imidazolyl) -3- (1- aziridino) -2-propanol .
  • the radiosensitizer agent is selected from the group consisting of 2- (3-nitro-l, 2 , 4-triazol-l-yl) -
  • the present invention provides a method according to Embodiment 25 wherein the anti-cancer agent is an anti-cancer agent agent.
  • the present invention provides a method of treating cancer according to Embodiment 25, wherein the administration is by injection or infusion.
  • the present invention provides the method of Embodiment 25, further comprising treating the cancer by brachytherapy, external beam radiation, laser therapy or surgical removal.
  • the present invention provides a kit comprising packaging material, and a therapeutic radiopharmaceutical composition of Embodiment 13, contained within said packaging material, wherein the packaging material comprises a label or package insert which indicates that said therapeutic radiopharmaceutical composition can be used for treating cancer.
  • the present invention provides a therapeutic radiopharmaceutical composition of Embodiment 13, further comprising a photosensitizing agent .
  • the present invention provides a therapeutic radiopharmaceutical composition according to Embodiment 46, wherein the photosensitizing agent is selected from the group consisting of photofrin; naphthalocyanine photosensitizing agents; tetrapyrrole-based photosensitizers; porphyins; chlorins;, phthalocyanines; napthalocyanines; coumarins, psoralens, 1, 3 , 4, 6-tetramethoxyhelianthrone; 10,13- dimethyl-1, 3,4, 6-tetrahydroxyhelianthrone; 10, 13- di (methoxycarbonyl) -1,3,4, 6-tetramethoxyhelianthrone; 1, 6-di-N-butylamino-3 , 4-dimethoxy-helianthrone; 1, 6-di- N-butylamino-3 , 4-dimethoxy-10 , 13-dimethyl-helianthrone;
  • the present invention provides a kit according to Embodiment 45, further comprising a photosensitizing agent.
  • the present invention provides a kit according to Embodiment 48, wherein the photosensitizing agent is selected from the group consisting of photofrin; naphthalocyanine photosensitizing agents; tetrapyrrole-based photosensitizers; porphyins; chlorins;, phthalocyanines; napthalocyanines; coumarins, psoralens, 1,3,4,6- tetramethoxyhelianthrone; 10, 13-dimethyl-l, 3,4,6- tetrahydroxyhelianthrone; 10 , 13-di (methoxycarbonyl) - 1,3,4, 6-tetramethoxyhelianthrone; 1, 6-di-N-butylamino- 3 , 4-dimethoxy-helianthrone; 1, 6-di-N-butylamino-3 , 4- dimethoxy-10, 13-dimethyl-helianthrone; l,6-di-(N
  • Embodiment 25 further comprising treating the patient with photodynamic therapy.
  • the present invention provides a method of treating cancer according to Embodiment 50, wherein the photodynamic therapy comprises : a) administering a therapeutic radiopharmaceutical of the present invention and a photosensitive agent (photoreactive agent) to a patient, said photosensitive agent having a characteristic light absorption waveband and being preferentially absorbed by abnormal tissue; b) providing an imaging device that is integral with a plurality of light sources and produces a signal used for imaging abnormal tissue at the internal treatment site, said light sources emitting light in a waveband corresponding to the characteristic light absorption waveband of the photosensitive agent, said waveband including wavelengths sufficiently long to penetrate through a dermal layer of the patient to the internal treatment site; (c) determining a location of the abnormal tissue at the internal targeted site within the body of the patient with the imaging device, by viewing an image of the abnormal tissue at the targeted site developed in response to the signal produced by the imaging device; and
  • the present invention provides a method of treating cancer according to
  • Embodiment 47 wherein the photosensitive agent (photoreactive agent) is specifically targeted at the targeted tissue by including a binding agent that selectively links the photosensitive agent to the targeted tissue.
  • the photosensitive agent photoreactive agent
  • the present invention provides a method of treating cancer according to Embodiment 51, wherein the photosensitizing agent is selected from the group consisting of photofrin; naphthalocyanine photosensitizing agents; tetrapyrrole- based photosensitizers; porphyins; chlorins; phthalocyanines; napthalocyanines ; coumarins, psoralens, 1,3,4, 6-tetramethoxyhelianthrone; 10, 13-dimethyl- 1,3,4, 6-tetrahydroxyhelianthrone; 10, 13- di (methoxycarbonyl) -1 , 3 , 4 , 6-tetramethoxyhelianthrone; 1, 6-di-N-butylamino-3 , 4-dimethoxy-helianthrone; 1, 6-di- N-butylamino-3 , 4-dimethoxy-10 , 13-dimethyl-helianthrone; 1, 6-di- (N-hydroxy
  • Diagnostic kits of the present invention comprise one or more vials containing the sterile, non-pyrogenic, formulation comprised of a predetermined amount of a reagent of the present invention, and optionally other components such as one or two ancillary ligands, reducing agents, transfer ligands, buffers, lyophilization aids, stabilization aids, solubilization aids and bacteriostats .
  • the inclusion of one or more optional components in the formulation will frequently improve the ease of synthesis of the radiopharmaceutical by the practicing end user, the ease of manufacturing the kit, the shelf-life of the kit, or the stability and shelf-life of the radiopharmaceutical.
  • the inclusion of one or two ancillary ligands is required for diagnostic kits comprising reagent comprising a hydrazine or hydrazone bonding moiety.
  • the one or more vials that contain all or part of the formulation can independently be in the form of a sterile solution or a lyophilized solid.
  • Another aspect of the present invention contemplates the combination of anti-cancer agents and angiogenesis-targeted therapeutic radiopharmaceuticals of the invention, which target the luminal side of the neovasculature of tumors, to provide a surprising, and enhanced degree of tumor suppression relative to each treatment modality alone without significant additive toxicity.
  • Another aspect of the present invention contemplates the compounds of the present invention (i.e. a compound comprising: a targeting moiety and a chelator, wherein the targeting moiety is bound to the chelator, is a peptide or peptidomimetic, and binds to a receptor that is upregulated during angiogenesis and the compound has 0-1 linking groups between the targeting moiety and chelator) which is administered in combination therapy, with one or more anti-cancer agent (s) selected from the group consisting of mitomycin, tretinoin, ribomustin, gemcitabine, vincristine, etoposide, cladribine, mitobronitol, methotrexate, doxorubicin, carboquone, pentostatin, nitracrine, zinostatin, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin
  • This combination therapy may further, optionally, include a radiosensitizer agent, or a pharmaceutically acceptable salt thereof, to enhance the radiotherapeutic effect together with the anti-cancer agent, said radiosensitizer agent being selected from the group consisting of 2- (3-nitro-l, 2 , 4-triazol-l-yl) -N- (2- methoxyethyl) acetamide, N- (3-nitro-4-quinolinyl) -4- morpholinecarboxamidine, 3-amino-l, 2 , 4-benzotriazine- 1, 4-dioxide, N- (2-hydroxyethyl) -2-nitroimidazole-l- acetamide, 1- (2-nitroimidazol-l-yl) -3- (1-piperidinyl) - 2-propanol, and 1- (2-nitro-l-imidazolyl) -3- (1- aziridino) -2-propanol .
  • a radiosensitizer agent being
  • kits having a plurality of active ingredients (with or without carrier) which, together, may be effectively utilized for carrying out the novel combination therapies of the invention.
  • the present invention provides a method for treating cancer in a patient in need of such treatment, said method including the steps of administering a therapeutically effective amount of a compound of the present invention and administering a therapeutically effective amount of at least one agent selected from the group consisting of an anti-cancer agent and a radiosensitizer agent.
  • any variable occurs more than one time in any substituent or in any formula, its definition on each occurrence is independent of its definition at every other occurrence.
  • a group is shown to be substituted with 0-2 R 52 , then said group may optionally be substituted with up to two R 52 , and R 52 at each occurrence is selected independently from the defined list of possible R 52 .
  • R 52 at each occurrence is selected independently from the defined list of possible R 52 .
  • each of the two R 53 substituents on N is independently selected from the defined list of possible R 53 .
  • Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.
  • a bond to a substituent is shown to cross the bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring.
  • reagent is meant a compound of this invention capable of direct transformation into a metallopharmaceutical of this invention. Reagents may be utilized directly for the preparation of the metallopharmaceuticals of this invention or may be a component in a kit of this invention.
  • binding agent means a metallopharmaceutical of this invention having affinity for and capable of binding to the vitronectin receptor. The binding agents of this invention preferably have Ki ⁇ 1000nM.
  • Metallopharmaceutical as used herein is intended to refer to a pharmaceutically acceptable compound containing a metal, wherein the compound is useful for imaging, magnetic resonance imaging, contrast imaging, or x-ray imaging. The metal is the cause of the imageable signal in diagnostic applications and the source of the cytotoxic radiation in radiotherapeutic applications.
  • Radiopharmaceuticals are metallopharmaceuticals in which the metal is a radioisotope.
  • stable compound or “stable structure” is meant herein a compound- that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious pharmaceutical agent.
  • substituted means that one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom's or group's normal valency is not exceeded, and that the substitution results in a stable compound.
  • 2 hydrogens on the atom are replaced.
  • bond means either a single or double bond.
  • salt is used as defined in the CRC Handbook of Chemistry and Physics, 65th Edition, CRC Press, Boca Raton, Fla, 1984, as any substance which yields ions, other than hydrogen or hydroxyl ions.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds modified by making acid or base salts. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • phrases "pharmaceutically acceptable” is employed herein to refer to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
  • prodrugs as used herein means those prodrugs of the compounds useful according to the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention.
  • prodrug means compounds that are rapidly transformed in vivo to yield the parent compound of the above formula, for example by hydrolysis in blood. Functional groups which may be rapidly transformed, by metabolic cleavage, in vivo form a class of groups reactive with the carboxyl group of the compounds of this invention.
  • alkanoyl such as acetyl, propionyl, butyryl, and the like
  • unsubstituted and substituted aroyl such as benzoyl and substituted benzoyl
  • alkoxycarbonyl such as ethoxycarbonyl
  • trialkylsilyl such as trimethyl- and triethysilyl
  • monoesters formed with dicarboxylic acids such as succinyl
  • the compounds bearing the metabolically cleavable groups have the advantage that they may exhibit improved bioavailability as a result of enhanced solubility and/or rate of absorption conferred upon the parent compound by virtue of the presence of the metabolically cleavable group.
  • prodrugs A thorough discussion of prodrugs is provided in the following: Design of Prodrugs, H. Bundgaard, ed. , Elsevier, 1985; Methods in Enzymology, K. Widder et al, Ed., Academic Press, 42, p.309-396, 1985; A Textbook of Drug Design and Development, Krogsgaard-Larsen and H. Bundgaard, ed.
  • pharmaceutically acceptable salts refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof.
  • pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, and the like.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like
  • organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, tartaric
  • the pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound which contains a basic or acidic moiety by conventional chemical methods.
  • such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical
  • alkyl is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms.
  • C ⁇ _ ⁇ o alkyl is intended to include Ci, C 2 , C 3 , C 4 , C 5 , CQ , C ⁇ , C % , Cg, and C 10 alkyl groups.
  • alkyl include, but are not limited to, methyl, ethyl, n-propyl, i-propyl, n-butyl, s-butyl, t-butyl, n-pentyl, and s-pentyl.
  • haloalkyl include, but are not limited to, trifluoromethyl, trichloromethyl, pentafluoroethyl, and pentachloroethyl .
  • Alkoxy represents an alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge.
  • C ⁇ _ ⁇ o alkoxy is intended to include Ci, C 2 , C 3 , C 4 , C 5 , C ⁇ , C ⁇ , C ⁇ , Cg, and C 10 alkoxy groups.
  • alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, s-butoxy, t-butoxy, n-pentoxy, and s-pentoxy.
  • Cycloalkyl is intended to include saturated ring groups, such as cyclopropyl, cyclobutyl, or cyclopentyl.
  • 0 3 - 7 cycloalkyl is intended to include C 3 , C 4 , C 5 , Cg, and C 7 cycloalkyl groups.
  • Alkenyl is intended to include hydrocarbon chains of either a straight or branched configuration and one or more unsaturated carbon-carbon bonds which may occur in any stable point along the chain, such as ethenyl and propenyl .
  • C 2 _ ⁇ o alkenyl is intended to include C , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 / Cg, and C 1 0 alkenyl groups.
  • Alkynyl is intended to include hydrocarbon chains of either a straight or branched configuration and one or more triple carbon-carbon bonds which may occur in any stable point along the chain, such as ethynyl and propynyl .
  • C - ⁇ o alkynyl is intended to include C 2 , C 3 , C 4 , C 5 , CQ , C ⁇ , C ⁇ , Cg, and C 10 alkynyl groups.
  • carrier or “carbocyclic residue” is intended to mean any stable 3, 4, 5, 6, or 7-r ⁇ embered monocyclic or bicyclic or 7 , 8, 9, 10, 11, 12, or 13-membered bicyclic or tricyclic, any of which may be saturated, partially unsaturated, or aromatic.
  • carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, adamantyl, cyclooctyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane, [2.2.2 ]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, and tetrahydronaphthyl .
  • alkaryl means an aryl group bearing an alkyl group of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms
  • aralkyl means an alkyl group of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms bearing an aryl group
  • arylalkaryl means an aryl group bearing an alkyl group of 1-10 carbon atoms bearing an aryl group
  • heterocycloalkyl means an alkyl group of 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms bearing a heterocycle.
  • heterocycle or “heterocyclic system” is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7 , 8, 9, or 10- membered bicyclic heterocyclic ring which is saturated, partially unsaturated or unsaturated (aromatic) , and which consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, NH, 0 and S and including any bicyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring.
  • the nitrogen and sulfur heteroatoms may optionally be oxidized.
  • the heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure.
  • the heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable.
  • a nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and 0 atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and 0 atoms in the heterocycle is not more than 1.
  • aromatic heterocyclic system or “heteroaryl” is intended to mean a stable 5, 6, or 7-membered monocyclic or bicyclic or 7, 8, 9, or 10-membered bicyclic heterocyclic aromatic ring which consists of carbon atoms and 1, 2, 3, or 4 heterotams independently selected from the group consisting of N, NH, 0 and S. It is to be noted that total number of S and 0 atoms in the aromatic heterocycle is not more than 1.
  • heterocycles include, but are not limited to, acridinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4aH-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2H, 6H-1, 5, 2-dithiazinyl, dihydrofuro [2 , 3-b] tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, lH-indazolyl, indolenyl, indolin
  • Preferred heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, imidazolyl, indolyl, benzimidazolyl, 1H- indazolyl, oxazolidinyl, benzotriazolyl, benzisoxazolyl, oxindolyl, benzoxazolinyl, and isatinoyl . Also included are fused ring and spiro compounds containing, for example, the above heterocycles.
  • polyalkylene glycol is a polyethylene glycol, polypropylene glycol or polybutylene glycol having a molecular weight of less than about 5000, terminating in either a hydroxy or alkyl ether moiety.
  • a “carbohydrate” is a polyhydroxy aldehyde, ketone, alcohol or acid, or derivatives thereof, including polymers thereof having polymeric linkages of the acetal type .
  • a "cyclodextrin” is a cyclic oligosaccharide .
  • cyclodextrins include, but are not limited to, -cyclodextrin, hydroxyethyl- -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, carboxymethyl- ⁇ -cyclodextrin, dihydroxypropyl- ⁇ -cyclodextrin, hydroxyethyl- ⁇ -cyclodextrin, 2,6 di-O-methyl- ⁇ -cyclodextrin, sulfated- ⁇ -cyclodextrin, ⁇ -cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin, dihydroxypropyl- ⁇ -eye1odextri , hydroxyethyl- ⁇ -cyclodextrin, and sulfated ⁇ -cyclodextr
  • polycarboxyalkyl means an alkyl group having between two and about 100 carbon atoms and a plurality of carboxyl substituents; and the term “polyazaalkyl” means a linear or branched alkyl group having between two and about 100 carbon atoms, interrupted by or substituted with a plurality of amine groups .
  • a “reducing agent” is a compound that reacts with a radionuclide, which is typically obtained as a relatively unreactive, high oxidation state compound, to lower its oxidation state by transferring electron (s) to the radionuclide, thereby making it more reactive.
  • Reducing agents useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to stannous chloride, stannous fluoride, formamidine sulfinic acid, ascorbic acid, cysteine, phosphines, and cuprous or ferrous salts. Other reducing agents are described in Brodack et . al . , PCT Application 94/22496, which is incorporated herein by reference.
  • a "transfer ligand” is a ligand that forms an intermediate complex with a metal ion that is stable enough to prevent unwanted side-reactions but labile enough to be converted to a metallopharmaceutical.
  • the formation of the intermediate complex is kinetically favored while the formation of the metallopharmaceutical is thermodynamically favored.
  • Transfer ligands useful in the preparation of metallopharmaceuticals and in diagnostic kits useful for the preparation of diagnostic radiopharmaceuticals include but are not limited to gluconate, glucoheptonate, mannitol, glucarate,
  • transfer ligands are comprised of oxygen or nitrogen donor atoms.
  • donor atom refers to the atom directly attached to a metal by a chemical bond.
  • Acillary or co-ligands are ligands that are incorporated into a radiopharmaceutical during its synthesis . They serve to complete the coordination sphere of the radionuclide together with the chelator or radionuclide bonding unit of the reagent.
  • the radionuclide coordination sphere is composed of one or more chelators or bonding units from one or more reagents and one or more ancillary or co-ligands, provided that there are a total of two types of ligands, chelators or bonding units.
  • a radiopharmaceutical comprised of one chelator or bonding unit from one reagent and two of the same ancillary or co-ligands and a radiopharmaceutical comprised of two chelators or bonding units from one or two reagents and one ancillary or co-ligand are both considered to be comprised of binary ligand systems .
  • the radionuclide coordination sphere is composed of one or more chelators or bonding units from one or more reagents and one or more of two different types of ancillary or co-ligands, provided that there are a total of three types of ligands, chelators or bonding units.
  • a radiopharmaceutical comprised of one chelator or bonding unit from one reagent and two different ancillary or co-ligands is considered to be comprised of a ternary ligand system.
  • Ancillary or co-ligands useful in the preparation of radiopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals are comprised of one or more oxygen, nitrogen, carbon, sulfur, phosphorus, arsenic, selenium, and tellurium donor atoms .
  • a ligand can be a transfer ligand in the synthesis of a radiopharmaceutical and also serve as an ancillary or co-ligand in another radiopharmaceutical.
  • a ligand is termed a transfer or ancillary or co-ligand depends on whether the ligand remains in the radionuclide coordination sphere in the radiopharmaceutical, which is determined by the coordination chemistry of the radionuclide and the chelator or bonding unit of the reagent or reagents .
  • a "chelator” or “bonding unit” is the moiety or group on a reagent that binds to a metal ion through the formation of chemical bonds with one or more donor atoms.
  • binding site means the site in vivo or in vitro that binds a biologically active molecule.
  • a “diagnostic kit” or “kit” comprises a collection of components, termed the formulation, in one or more vials which are used by the practicing end user in a clinical or pharmacy setting to synthesize diagnostic radiopharmaceuticals .
  • the kit provides all the requisite components to synthesize and use the diagnostic radiopharmaceutical except those that are commonly available to the practicing end user, such as water or saline for injection, a solution of the radionuclide, equipment for heating the kit during the synthesis of the radiopharmaceutical, if required, equipment necessary for administering the radiopharmaceutical to the patient such as syringes and shielding, and imaging equipment.
  • Radiopharmaceuticals, X-ray contrast agent pharmaceuticals, ultrasound contrast agent pharmaceuticals and metallopharmaceuticals for magnetic resonance imaging contrast are provided to the end user in their final form in a formulation contained typically in one vial, as either a lyophilized solid or an aqueous solution.
  • the end user reconstitutes the lyophilized with water or saline and withdraws the patient dose or just withdraws the dose from the aqueous solution formulation as provided.
  • a "lyophilization aid” is a component that has favorable physical properties for lyophilization, such as the glass transition temperature, and is added to the formulation to improve the physical properties of the combination of all the components of the formulation for lyophi1ization .
  • a “stabilization aid” is a component that is added to the metallopharmaceutical or to the diagnostic kit either to stabilize the metallopharmaceutical or to prolong the shelf-life of the kit before it must be used.
  • Stabilization aids can be antioxidants , reducing agents or radical scavengers and can provide improved stability by reacting preferentially with species that degrade other components or the metallopharmaceutical.
  • a “solubilization aid” is a component that improves the solubility of one or more other components in the medium required for the formulation.
  • a “bacteriostat” is a component that inhibits the growth of bacteria in a formulation either during its storage before use of after a diagnostic kit is used to synthesize a radiopharmaceutical.
  • amino acid as used herein means an organic compound containing both a basic amino group and an acidic carboxyl group. Included within this term are natural amino acids (e.g., L-amino acids), modified and unusual amino acids (e.g., D-amino acids), as well as amino acids which are known to occur biologically in free or combined form but usually do not occur in proteins. Included within this term are modified and unusual amino acids, such as those disclosed in, for example, Roberts and Vellaocio (1983) The Peptides , 5: 342-429, the teaching of which is hereby incorporated by reference.
  • Natural protein occurring amino acids include, but are not limited to, alanine, arginine, asparagine, aspartic acid, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, serine, threonine, tyrosine, tyrosine, tryptophan, proline, and valine.
  • Natural non-protein amino acids include, but are not limited to arginosuccinic acid, citrulline, cysteine sulfinic acid, 3 , 4-dihydroxyphenylalanine, homocysteine, homoserine, ornithine, 3-monoiodotyrosine, 3 , 5-diiodotryosine, 3 , 5, 5 ' -triiodothyronine, and
  • Modified or unusual amino acids which can be used to practice the invention include, but are not limited to, D-amino acids, hydrox lysine, 4-hydroxyproline, an N-Cbz-protected amino acid, 2 , 4-diaminobutyric acid, homoarginine, norleucine, N-methylaminobutyric acid, naphthylalanine, phenylglycine, ⁇ -phenylproline, tert-leucine, 4-aminocyclohexylalanine, N-methyl-norleucine, 3 , 4-dehydroproline, N,N-dimethylaminoglycine, N-methylaminoglycine, 4-aminopiperidine-4-carboxylic acid, 6-aminocaproic acid, trans-4- (aminomethyl) -cyclohexanecarboxylic acid, 2-
  • peptide as used herein means a linear compound that consists of two or more amino acids (as defined herein) that are linked by means of a peptide bond.
  • a "peptide” as used in the presently claimed invention is intended to refer to a moiety with a molecular weight of less than 10,000 Daltons, preferable less than 5,000 Daltons, and more preferably less than 2,500 Daltons.
  • the term “peptide” also includes compounds containing both peptide and non-peptide components, such as pseudopeptide or peptidomimetic residues or other non-amino acid components . Such a compound containing both peptide and non-peptide components may also be referred to as a "peptide analog" .
  • a “pseudopeptide” or “peptidomimetic” is a compound which mimics the structure of an amino acid residue or a peptide, for example, by using linking groups other than amide linkages between the peptide mimetic and an amino acid residue (pseudopeptide bonds) and/or by using non-amino acid substituents and/or a modified amino acid residue.
  • a “pseudopeptide residue” means that portion of an pseudopeptide or peptidomimetic that is present in a peptide.
  • the term “peptide bond” means a covalent amide linkage formed by loss of a molecule of water between the carboxyl group of one amino acid and the amino group of a second amino acid.
  • peptide bonds includes peptide bond isosteres which may be used in place of or as substitutes for the normal amide linkage. These substitute or amide "equivalent” linkages are formed from combinations of atoms not normally found in peptides or proteins which mimic the spatial requirements of the amide bond and which should stabilize the molecule to enzymatic degradation.
  • the pharmaceuticals of the present invention are comprised of a targeting moiety for a receptor that is expressed or upregulated in angiogenic tumor vasculature.
  • the targeting moieties are comprised of peptides or peptidomimetics that bind with high affinity to the receptors.
  • peptides comprised of a 23 amino acid portion of the C- terminal domain of VEGF have been synthesized which competitively inhibit binding of VEGF to VEGFR (Soker, et. al., J. Biol. Chem., 1997, 272, 31582-8).
  • Linear peptides of 11 to 23 amino acid residues that bind to the basic FGF receptor are described by Cosic et. al., Mol. and Cell. Biochem., 1994, 130, 1-9.
  • a preferred linear peptide antagonist of the bFGFR is the 16 amino acid peptide, Met-Trp-Tyr-Arg-Pro-Asp-Leu-Asp- Glu-Arg-Lys-Gln-Gln-Lys-Arg-Glu.
  • Gho et . al . (Cancer Research, 1997, 57, 3733-40) describe the identification of small peptides that bind with high affinity to the angiogenin receptor on the surface of endothelial cells.
  • a preferred peptide is Ala-Gln-Leu-Ala-Gly-Glu-Cys-Arg- Glu-Asn-Val-Cys-Met-Gly-Ile-Glu-Gly-Arg, in which the two Cys residues form an intramolecular disulfide bond.
  • Yayon et . al . (Proc. Natl. Acad. Sci, USA, 1993, 90, 10643-7) describe other linear peptide antagonists of FGFR, identified from a random phage-displayed peptide library.
  • Targeting moieties for integrins expressed in tumor vasculature include peptides and peptidomimetics that bind to ⁇ v ⁇ 3 , O v ⁇ s, ⁇ s ⁇ i, ⁇ 4 ⁇ , (Xi ⁇ i, and ⁇ 2 . Pierschbacher and Rouslahti (J. Biol.
  • the targeting moieties of the present invention preferably, have a binding affinity for the integrin ⁇ v ⁇ 3 of less than lOOOnM. More preferably, the targeting moieties of the present invention, preferably, have a binding affinity for the integrin 0 ⁇ 3 of less than lOOnM. Even more preferably, the targeting moieties of the present invention, preferably, have a binding affinity for the integrin Oy ⁇ s of less than lOnM.
  • the ultrasound contrast agents of the present invention comprise a plurality of angiogenic tumor vasculature targeting moieties attached to or incorporated into a microbubble of a biocompatible gas, a liquid carrier, and a surfactant microsphere, further comprising an optional linking moiety, L n , between the targeting moieties and the microbubble.
  • liquid carrier means aqueous solution
  • surfactant means any amphiphilic material which produces a reduction in interfacial tension in a solution.
  • surfactant microsphere includes nanospheres, liposomes, vesicles and the like.
  • the biocompatible gas can be air, or a fluorocarbon, such as a C 3 -C 5 perfluoroalkane, for example, perflouropropane, perflourobutane, or perflouroperitanfe, which provides the difference in echogenicity and thus the contrast in ultrasound imaging.
  • the gas is encapsulated or contained in the microsphere to which is attached the biodirecting group, optionally via a linking group.
  • the attachment can be covalent, ionic or by van der Waals forces.
  • Specific examples of such contrast agents include lipid encapsulated perfluorocarbons with a plurality of tumor neovasculature receptor binding peptides or peptidomimetics .
  • S f as used herein is a surfactant which is either a lipid or a compound of the formula A 1 -E-A 2 , defined above.
  • the surfactant is intended to form a vesicle (e.g., a microsphere) capable of containing an echogenic gas.
  • the ultrasound contrast agent compositions of the present invention are intended to be capable upon agitation (e.g., shaking, stirring, etc ... ) of encapsulating an echogenic gas in a vescicle in such a way as to allow for the resultant product to be useful as an ultrasound contrast agent.
  • Vesicle refers to a spherical entity which is characterized by the presence of an internal void.
  • Preferred vesicles are formulated from lipids, including the various lipids described herein.
  • the lipids may be in the form of a monolayer or bilayer, and the mono- or bilayer lipids may be used to form one of more mono- or bilayers .
  • the mono- or bilayers are generally concentric.
  • the lipid vesicles described herein include such entities commonly referred to as liposomes, micelles, bubbles, microbubbles, microspheres and the like.
  • the lipids may be used to form a unilamellar vesicle (comprised of one monolayer or bilayer) , an oligolamellar vesicle (comprised of about two or about three monolayers or bilayers) or a multilamellar vesicle (comprised of more than about three monolayers or bilayers) .
  • the internal void of the vesicles may be filled with a liquid, including, for example, an aqueous liquid, a gas, a gaseous precursor, and/or a solid or solute material, including, for example, a bioactive agent, as desired.
  • Vesicular composition refers to a composition ⁇ which is formulate from lipids and which comprises vesicles .
  • Vehicle formulation refers to a composition which comprises vesicles and a bioactive agent.
  • Microsphere is preferably a sphere of less than or equal to 10 microns.
  • Liposome may include a single lipid layer (a lipid monolayer) , two lipid layers (a lipid bilayer) or more than two lipid layers (a lipid multilayer) .
  • Lipomes refers to a generally spherical cluster or aggregate of amphipathic compounds, including lipid compounds, typically in the form of one or more concentric layers, for example, bilayers. They may also be referred to herein as lipid vesicles.
  • bubbles refers to vesicles which are generally characterized by the presence of one or more membranes or walls surrounding an internal void that is filled with a gas or precursor thereto.
  • Exemplary bubbles include, for example, liposomes, micelles and the like.
  • Lipid refers to a synthetic or naturally- occurring amphipathic compound which comprises a hydrophilic component and a hydrophobic component.
  • Lipids include, for example, fatty acids, neutral fats, phosphatides, glycolipids, aliphatic alchols and waxes, terpenes and steroids.
  • Lipid composition refers to a composition which comprises a lipid compound.
  • exemplary lipid compositions include suspensions, emulsions and vesicular compositions.
  • Lipid formulation refers to a composition which comprises a lipid compound and a bioactive agent.
  • suitable lipids and specific suitable lipids include: phosphatidylcholines , such as dioleoylphosphatidylcholine, dimyristoylphosphatidylcholine, dipalmitoylphosphatidylchol-ine (DPPC) , and distearoylphosphatidylcholine; phosphatidylethanolamines, such as dipalmitoylphosphatidylethanolamine (DPPE) , dioleoylphosphatidylethanolamine and N-succinyl- dioleoylphosphatidylethanolamine; phosphatidylserines; phosphatidylglycerols; sphingolipids ; glycolipids, such as ganglioside.
  • phosphatidylcholines such as dioleoylphosphatidylcholine, dimyristoylphosphatidy
  • GMl glucolipids; sulfatides; glycosphingolipids; phosphatidic acids, such as dipalmatoylphosphatidic acid (DPPA) ; palmitic fatty acids; stearic fatty acids; arachidonic fatty acids; lauric fatty acids; myristic fatty acids; lauroleic fatty acids; physeteric fatty acids; myristoleic fatty acids; palmitoleic fatty acids; petroselinic fatty acids; oleic fatty acids; isolauric fatty acids; isomyristic fatty acids; isopalmitic fatty acids; isostearic fatty acids; cholesterol and cholesterol derivatives, such as cholesterol hemisuccinate, cholesterol sulfate, and cholesteryl- (4 ' - trimethylammonio) -butanoate; polyoxyethylene fatty acid esters; polyoxyethylene fatty acid alcohols; polyoxyethylene fatty acid alcohol ethers; polyoxyethylated sorb
  • the echogenic gas may be one gas or mixture of gases, such as CF4, C2F6, C3F8, cyclo-C4F8, C4F10, C5F12, cyclo-C5F ⁇ o,cyclo-C4F7 ( 1-trifluoromethyl) , propane (2-trifluoromethyl) -1, 1, 1, 3 , 3 , 3 hexafluoro, and butane (2-trifluoromethyl) -1, 1, 1, 3 , 3 , 3 , 4, 4 , 4 nonafluoro.
  • gases such as CF4, C2F6, C3F8, cyclo-C4F8, C4F10, C5F12, cyclo-C5F ⁇ o,cyclo-C4F7 ( 1-trifluoromethyl) , propane (2-trifluoromethyl) -1, 1, 1, 3 , 3 , 3 hexafluoro, and butane (2-trifluoromethyl) -1, 1, 1, 3 , 3 , 3 , 4,
  • X-ray contrast agents of the present invention are comprised of one or more angiogenic tumor vasculature targeting moieties attached to one or more X-ray absorbing or "heavy" atoms of atomic number 20 or greater, further comprising an optional linking moiety, L n , between the targeting moieties and the X-ray absorbing atoms.
  • X-ray contrast agents comprised of metal chelates (Wallace, R. , U.S. 5,417,959) and polychelates comprised of a plurality of metal ions (Love, D. , U.S. 5,679,810) have been disclosed. More recently, multinuclear cluster complexes have been disclosed as X-ray contrast agents (U.S. 5,804,161, PCT WO91/14460, and PCT WO 92/17215).
  • X-ray agents include the non-radioactive or naturally occurring analogs of the above listed radionuclides (e.g., Re, Sm, Ho, Lu, Pm, Y, Bi, Pd, Gd, La, Au, Au, Yb, Dy, Cu, Rh, Ag, and Ir) .
  • radionuclides e.g., Re, Sm, Ho, Lu, Pm, Y, Bi, Pd, Gd, La, Au, Au, Yb, Dy, Cu, Rh, Ag, and Ir
  • MRI contrast agents of the present invention are comprised of one or more angiogenic tumor vasculature targeting moieties attached to one or more paramagnetic metal ions, further comprising an optional linking moiety, L n , between the targeting moieties and the paramagnetic metal ions .
  • the paramagnetic metal ions are present in the form of metal complexes or metal oxide particles.
  • U.S. 5,412,148, and 5,760,191 describe examples of chelators for paramagnetic metal ions for use in MRI contrast agents.
  • U.S. 5,801,228, U.S. 5,567,411, and U.S. 5,281,704 describe examples of polychelants useful for complexing more than one paramagnetic metal ion for use in MRI contrast agents.
  • U.S. 5,520,904 describes particulate compositions comprised of paramagnetic metal ions for use as MRI contrast agents.
  • Administration of a compound of the present invention in combination with such additional therapeutic agents may afford an efficacy advantage over the compounds and agents alone, and may do so while permitting the use of lower doses of each.
  • a lower dosage minimizes the potential of side effects, thereby providing an increased margin of safety.
  • the combination of a compound of the present invention with such additional therapeutic agents is preferably a synergistic combination. Synergy, as described for example by Chou and Talalay, Adv. Enzyme Regul . 22:27-55 (1984), occurs when the therapeutic effect of the compound and agent when administered in combination is greater than the additive effect of the either the compound or agent when administered alone.
  • synergistic effect is most clearly demonstrated at levels that are (therapeutically) sub-optimal for either the compound of the present invention, an anti-cancer agent, a photosensitizer agent or a radiosensitizer agent alone, but which are highly efficacious in combination.
  • Synergy can be in terms of improved tumor response without substantial increases in toxicity over individual treatments alone, or some other beneficial effect of the combination compared with the individual components .
  • the compounds of the present invention, and an anti-cancer agent or a radiosensitizer agent, utilized in combination therapy may be administered simultaneously, in either separate or combined formulations, or at different times e.g., sequentially, such that a combined effect is achieved.
  • the amounts and regime of administration will be adjusted by the practitioner, by preferably initially lowering their standard doses and then titrating the results obtained.
  • kits or single packages combining two or more active ingredients useful in treating cancer.
  • a kit may provide (alone or in combination with a pharmaceutically acceptable diluent or carrier) , the compound of the present invention and additionally at least one agent selected from the group consisting of an anti-cancer agent and a radiosensitizer agent (alone or in combination with diluent or carrier) and a photosensitizer agent.
  • the pharmaceuticals of the present invention have the formulae, (Q) d -L n - (C h -X) , (Q) d -L n - (Ch-X 1 ) d' , (Q) a ⁇ L n - (X 2 ) d " and (Q) a -L n ⁇ ( ⁇ 3 ) wherein Q represents a peptide or peptidomimetic that binds to a receptor expressed in angiogenic tumor vasculature, d is 1-10, L n represents an optional linking group, C represents a metal chelator or bonding moiety, X represents a radioisotope, X 1 represents paramagnetic metal ion, X 2 represents a paramagnetic metal ion or heavy atom containing insoluble solid particle, d" is 1-100, and X 3 represents a surfactant microsphere of an echogenic gas.
  • Preferred pharmaceuticals of the present invention are comprised of targeting moieties, Q, that are peptides and peptidomimetics that bind to the vitronectin receptors 0 ⁇ 3 and Oy ⁇ s . More preferred pharmaceuticals of the present invention are comprised of targeting moieties, Q, that are peptides and peptidomimetics that bind to ⁇ v ⁇ 3 .
  • Most preferred pharmaceuticals of the present invention are comprised of ⁇ 3 targeting moieties, Q, that are comprised of one to ten cyclic pentapeptides or peptidomimetics, independently attached to a therapeutic radioisotope or imageable moiety, further comprising an optional linking moiety, L n , between the targeting moieties and the therapeutic radioisotopes or imageable moieties.
  • the cyclic peptides are comprised of a tripeptide sequence that binds to the ⁇ v ⁇ 3 receptor and two amino acids either one of which can be attached to L n , C h / X 2 , or X 3 .
  • the interaction of the tripeptide recognition sequences of the cyclic peptide or peptidomimetic portion of the pharmaceuticals with the ⁇ v ⁇ 3 receptor results in localization of the pharmaceuticals in angiogenic tumor vasculature, which express the ⁇ v ⁇ 3 receptor.
  • the pharmaceuticals of the present invention can be synthesized by several approaches .
  • One approach involves the synthesis of the targeting peptide or peptidomimetic moiety, Q, and direct attachment of one or more moieties, Q, to one or more metal chelators or bonding moieties, C / or to a paramagnetic metal ion or heavy atom containing solid particle, or to an echogenic gas microbubble.
  • Another approach involves the attachment of one or more moieties, Q, to the linking group, L n , which is then attached to one or more metal chelators or bonding moieties, C h or to a paramagnetic metal ion or heavy atom containing solid particle, or to an echogenic gas microbubble.
  • Another approach, useful in the synthesis of pharmaceuticals wherein d is 1, involves the synthesis of the moiety, Q-L n , together, by incorporating an amino acid or amino acid mimetic residue bearing L n into the synthesis of the peptide or peptidomimetic.
  • the resulting moiety, Q-L n is then attached to one or more metal chelators or bonding moieties, C h / or to a paramagnetic metal ion or heavy atom containing solid particle, or to an echogenic gas microbubble.
  • Another approach involves the synthesis of a peptide or peptidomimetic, Q, bearing a fragment of the linking group, L n , one or more of which are then attached to the remainder of the linking group and then to one or more metal chelators or bonding moieties, C h , or to a paramagnetic metal ion or heavy atom containing solid particle, or to an echogenic gas microbubble.
  • the peptides or peptidomimetics, Q optionally bearing a linking group, L n , or a fragment of the linking group, can be synthesized using standard synthetic methods known to those skilled in the art. Preferred methods include but are not limited to those methods described below.
  • peptides and peptidomimetics are elongated by deprotecting the alpha-amine of the C-terminal residue and coupling the next suitably protected amino acid through a peptide linkage using the methods described. This deprotection and coupling procedure is repeated until the desired sequence is obtained.
  • This coupling can be performed with the constituent amino acids in a stepwise fashion, or condensation of fragments (two to several amino acids) , or combination of both processes, or by solid phase peptide synthesis according to the method originally described by Merrifield, J. Am. Chem. Soc, 85,
  • the peptides and peptidomimetics may also be synthesized using automated synthesizing equipment.
  • procedures for peptide and peptidomimetic synthesis are described in Stewart and Young, "Solid Phase Peptide Synthesis", 2nd ed, Pierce Chemical Co., Rockford, IL (1984); Gross, Meienhofer, Udenfriend, Eds., "The Peptides: Analysis, Synthesis, Biology, Vol. 1, 2, 3, 5, and 9, Academic Press, New York, (1980-1987); Bodanszky, "Peptide Chemistry: A Practical Textbook", Springer-Verlag, New York (1988); and Bodanszky et al . "The Practice of Peptide Synthesis” Springer-Verlag, New York (1984), the disclosures of which are hereby incorporated by reference.
  • the coupling between two amino acid derivatives, an amino acid and a peptide or peptidomimetic, two peptide or peptidomimetic fragments, or the cyclization of a peptide or peptidomimetic can be carried out using standard coupling procedures such as the azide method, mixed carbonic acid anhydride (isobutyl chloroformate) method, carbodiimide (dicyclohexylcarbodiimide, diisopropylcarbodiimide, or water-soluble carbodiimides) method, active ester (p-nitrophenyl ester, N-hydroxysuccinic imido ester) method, Woodward reagent K method, carbonyldiimidazole method, phosphorus reagents such as BOP-C1, or oxidation-reduction method. Some of these methods (especially the carbodiimide) can be enhanced by the addition of 1-hydroxybenzotriazole. These coupling reactions may be performed in either solution (liquid phase) or solid phase.
  • the functional groups of the constituent amino acids or amino. acid mimetics must be protected during the coupling reactions to avoid undesired bonds being formed.
  • the protecting groups that can be used are listed in Greene, "Protective Groups in Organic Synthesis” John Wiley & Sons, New York (1981) and "The Peptides: Analysis, Synthesis, Biology, Vol. 3, Academic Press, New York (1981) , the disclosure of which is hereby incorporated by reference.
  • the alpha-carboxyl group of the C-terminal residue is usually protected by an ester that can be cleaved to give the carboxylic acid.
  • These protecting groups include: 1) alkyl esters such as methyl and t-butyl, 2) aryl esters such as benzyl and substituted benzyl, or 3) esters which can be cleaved by mild base treatment or mild reductive means such as trichloroethyl and phenacyl esters.
  • the C-terminal amino acid is attached to an insoluble carrier (usually polystyrene) .
  • insoluble carriers contain a group which will react with the carboxyl group to form a bond which is stable to the elongation conditions but readily cleaved later. Examples of which are: oxime resin
  • alpha-amino group of each amino acid must be protected. Any protecting group known in the art can be used. Examples of these are: 1) acyl types such as formyl, trifluoroacetyl, phthalyl, and p-toluenesulfonyl; 2) aromatic carbamate types such as benzyloxycarbonyl (Cbz) and substituted benzyloxycarbonyls ,
  • aliphatic carbamate types such as tert-butyloxycarbonyl (Boc) , ethoxycarbonyl, diisopropylmethoxycarbonyl, and allyloxycarbonyl; 4) cyclic alkyl carbamate types such as cyclopentyloxycarbonyl and adamantyloxycarbonyl; 5) alkyl types such as triphenylmethyl and benzyl; 6) trialkylsilane such as trimethylsilane; and 7) thiol containing types such as phenylthiocarbonyl and dithiasuccinoyl .
  • the preferred alpha-amino protecting group is either Boc or Fmoc. Many amino acid or amino acid mimetic derivatives suitably protected for peptide synthesis are commercially available.
  • the alpha-amino protecting group is cleaved prior to the coupling of the next amino acid.
  • the methods of choice are trifluoroacetic acid, neat or in dichloromethane, or HCI in dioxane.
  • the resulting ammonium salt is then neutralized either prior to the coupling or in situ with basic solutions such as aqueous buffers, or tertiary amines in dichloromethane or dimethylformamide.
  • the reagents of choice are piperidine or substituted piperidines in dimethylformamide, but any secondary amine or aqueous basic solutions can be used.
  • the deprotection is carried out at a temperature between 0 °C and room temperature.
  • any of the amino acids or amino acid mimetics bearing side chain functionalities must be protected during the preparation of the peptide using any of the above-identified groups.
  • Those skilled in the art will appreciate that the selection and use of appropriate protecting groups for these side chain functionalities will depend upon the amino acid or amino acid mimetic and presence of other protecting groups in the peptide or peptidomimetic. The selection of such a protecting group is important in that it must not be removed during the deprotection and coupling of the alpha-amino group.
  • Boc when Boc is chosen for the alpha-amine protection the following protecting groups are acceptable: p-toluenesulfonyl (tosyl) moieties and nitro for arginine; benzyloxycarbonyl, substituted benzyloxycarbonyls, tosyl or trifluoroacetyl for lysine; benzyl or alkyl esters such as cyclopentyl for glutamic and aspartic acids; benzyl ethers for serine and threonine; benzyl ethers, substituted benzyl ethers or 2-bromobenzyloxycarbonyl for tyrosine; p-methylbenzyl, p-methoxybenzyl, acetamidomethyl, benzyl, or t-butylsulfonyl for cysteine; and the indole of tryptophan can either be left unprotected or protected with a formyl group.
  • tert-butyl based protecting groups are acceptable.
  • Boc can be used for lysine, tert-butyl ether for serine, threonine and tyrosine, and tert-butyl ester for glutamic and aspartic acids.
  • the peptide or peptidomimetic When a solid phase synthesis is used to synthesize a cyclic peptide or peptidomimetic, the peptide or peptidomimetic should be removed from the resin without simultaneously removing protecting groups from functional groups that might interfere with the cyclization process. Thus, if the peptide or peptidomimetic is to be cyclized in solution, the cleavage conditions need to be chosen such that a free a-carboxylate and a free a-amino group are generated without simultaneously removing other protecting groups.
  • the peptide or peptidomimetic may be removed from the resin by hydrazinolysis, and then coupled by the azide method.
  • Another very convenient method involves the synthesis of peptides or peptidomimetics on an oxime resin, followed by intramolecular nucleophilic displacement from the resin, which generates a cyclic peptide or peptidomimetic (Osapay, Profit, and Taylor (1990) Tetrahedron Letters 43, 6121-6124) .
  • the Boc protection scheme is generally chosen.
  • the preferred method for removing side chain protecting groups generally involves treatment with anhydrous HF containing additives such as dimethyl sulfide, anisole, thioanisole, or p-cresol at 0 °C.
  • anhydrous HF containing additives such as dimethyl sulfide, anisole, thioanisole, or p-cresol at 0 °C.
  • the cleavage of the peptide or peptidomimetic can also be accomplished by other acid reagents such as trifluoromethanesulfonic acid/trifluoroacetic acid mixtures.
  • Unusual amino acids used in this invention can be synthesized by standard methods familiar to those skilled in the art ("The Peptides: Analysis, Synthesis, Biology, Vol. 5, pp. 342-449, Academic Press, New York (1981)) .
  • N-Alkyl amino acids can be prepared using procedures described in previously (Cheung et al . , (1977) Can. J. Chem. 55, 906; Freidinger et al . , (1982) J. Org. Chem. 48, 77 (1982)), which are incorporated herein by reference.
  • linking groups, L n to the peptides and peptidomimetics, Q; chelators or bonding units, C , to the peptides and peptidomimetics, Q, or to the linking groups, L n ; and peptides and peptidomimetics bearing a fragment of the linking group to the remainder of the linking group, in combination forming the moiety, (Q)a ⁇ L n , and then to the moiety C h ; can all be performed by standard techniques. These include, but are not limited to, amidation, esterification, alkylation, and the formation of ureas or thioureas. Procedures for performing these attachments can be found in Brinkley, M.
  • the coupling groups can be any of a number of silanes which react with surface hydroxyl groups on the solid particle surface, as described in co-pending U.S.A.N 60/092,360, and can also include polyphosphonates, polycarboxylates , polyphosphates or mixtures thereof which couple with the surface of the solid particles, as described in U.S. 5,520,904.
  • reaction schemes can be used to attach the peptides and peptidomimetics, Q, to the surfactant microsphere, X 3 . These are illustrated in following reaction schemes where S f represents a surfactant moiety that forms the surfactant microsphere.
  • Y is a leaving group or active ester
  • First it provides a spacing group between the metal chelator or bonding moiety, C h , the paramagnetic metal ion or heavy atom containing solid particle, X 2 , and the surfactant microsphere, X 3 , and the one or more of the peptides or peptidomimetics, Q, so as to minimize the possibility that the moieties C - , C h -X 1 , X 2 , and X 3 , will interfere with the interaction of the recognition sequences of Q with angiogenic tumor vasculature receptors.
  • the necessity of incorporating a linking group in a reagent is dependent on the identity of Q, Ch-X, Ch-X 1 , X 2 , and X 3 .
  • a linking group also provides a means of independently attaching multiple peptides and peptidomimetics, Q, to one group that is attached to C h ⁇ X, Ch-X 1 , X 2 , or X 3 .
  • the linking group also provides a means of incorporating a pharmacokinetic modifier into the pharmaceuticals of the present invention.
  • the pharmacokinetic modifier serves to direct the biodistibution of the injected pharmaceutical other than by the interaction of the targeting moieties, Q, with the receptors expressed in the tumor neovasculature.
  • a wide variety of functional groups can serve as pharmacokinetic modifiers, including, but not limited to, carbohydrates, polyalkylene glycols, peptides or other polyamino acids, and cyclodextrins .
  • the modifiers can be used to enhance or decrease hydrophilicity and to enhance or decrease the rate of blood clearance.
  • the modifiers can also be used to direct the route of elimination of the pharmaceuticals.
  • Preferred pharmacokinetic modifiers are those that result in moderate to fast blood clearance and enhanced renal excretion.
  • the metal chelator or bonding moiety, C is selected to form stable complexes with the . metal ion chosen for the particular application.
  • Chelators or bonding moieties for diagnostic radiopharmaceuticals are selected to form stable complexes with the radioisotopes that have imageable gamma ray or positron emissions, such as 99m Tc , 95 C; lllm, 62 Cu, 60 Cu, 6 Cu, 67 Ga, 68 Ga, 86 Y.
  • Chelators for technetium, copper and gallium isotopes are selected from diaminedithiols, monoamine-monoamidedithiols , triamide-monothiols , monoamine-diamide-monothiols, diaminedioximes, and hydrazines.
  • the chelators are generally tetradentate with donor atoms selected from nitrogen, oxygen and sulfur.
  • Preferred reagents are comprised of chelators having amine nitrogen and thiol sulfur donor atoms and hydrazine bonding units.
  • the thiol sulfur atoms and the hydrazines may bear a protecting group which can be displaced either prior to using the reagent to synthesize a radiopharmaceutical or preferably in situ during the synthesis of the radiopharmaceutical.
  • Exemplary thiol protecting groups include those listed in Greene and Wuts, "Protective Groups in Organic Synthesis” John Wiley & Sons, New York (1991) , the disclosure of which is hereby incorporated by reference. Any thiol protecting group known in the art can be used. Examples of thiol protecting groups include, but are not limited to, the following: acetamidomethyl, benzamidomethy1, 1-ethoxyethyl, benzoyl, and triphenylmethyl .
  • Exemplary protecting groups for hydrazine bonding units are hydrazones which can be aldehyde or ketone hydrazones having substituents selected from hydrogen, alkyl, aryl and heterocycle. Particularly preferred hydrazones are described in co-pending U.S.S.N. 08/476,296 the disclosure of which is herein incorporated by reference in its entirety.
  • the hydrazine bonding unit when bound to a metal radionuclide is termed a hydrazido, or diazenido group and serves as the point of attachment of the radionuclide to the remainder of the radiopharmaceutical.
  • a diazenido group can be either terminal (only one atom of the group is bound to the radionuclide) or chelating. In order to have a chelating diazenido group at least one other atom of the group must also be bound to the radionuclide.
  • the atoms bound to the metal are termed donor atoms .
  • Chelators for 11;L In and 86 Y are selected from cyclic and acyclic polyaminocarboxylates such as DTPA, DOTA, D03A, 2-benzyl-DOTA, alpha- (2-phenethyl) 1, 4, 7 , 10- tetraazazcyclododecane-l-acetic-4, 7, 10- tris (methylacetic) acid, 2-benzyl- cyclohexyldiethylenetriaminepentaacetic acid, 2-benzyl-
  • the coordination sphere of metal ion includes all the ligands or groups bound to the metal.
  • a transition metal radionuclide to be stable it typically has a coordination number (number of donor atoms) comprised of an integer greater than or equal to 4 and less than or equal to 8; that is there are 4 to 8 atoms bound to the metal and it is sai to have a complete coordination sphere.
  • the requisite coordination number for a stable radionuclide complex is determined by the identity of the radionuclide, its oxidation state, and the type of donor atoms.
  • the coordination sphere is completed by donor atoms from other ligands, termed ancillary or co-ligands, which can also be either terminal or chelating.
  • a large number of ligands can serve as ancillary or co-ligands, the choice of which is determined by a variety of considerations such as the ease of synthesis of the radiopharmaceutical, the chemical and physical properties of the ancillary ligand, the rate of formation, the yield, and the number of isomeric forms of the resulting radiopharmaceuticals, the ability to administer said ancillary or co-ligand to a patient without adverse physiological consequences to said patient, and the compatibility of the ligand in a lyophilized kit formulation.
  • the charge and lipophilicity of the ancillary ligand will effect the charge and lipophilicity of the radiopharmaceuticals.
  • Preferred technetium radiopharmaceuticals of the present invention are comprised of a hydrazido or diazenido bonding unit and an ancillary ligand, A L I, or a bonding unit and two types of ancillary A L I and A L2 , or a tetradentate chelator comprised of two nitrogen and two sulfur atoms.
  • Ancillary ligands A L I are comprised of two or more hard donor atoms such as oxygen and amine nitrogen (sp 3 hybridized) .
  • the donor atoms occupy at least two of the sites in the coordination sphere of the radionuclide metal; the ancillary ligand A I serves as one of the three ligands in the ternary ligand system.
  • ancillary ligands A L I include but are not limited to dioxygen ligands and functionalized aminocarboxylates . ' " A large number of such ligands are available from commercial sources.
  • Ancillary dioxygen ligands include ligands that coordinate to the metal ion through at least two oxygen donor atoms. Examples include but are not limited to: glucoheptonate, gluconate, 2-hydroxyisobutyrate, lactate, tartrate, mannitol, glucarate, maltol, Kojic acid, 2 , 2-bis (hydroxymethyl)propionic acid, 4, 5-dihydroxy-l, 3-benzene disulfonate, or substituted or unsubstituted 1,2 or 3,4 hydroxypyridinones . (The names for the ligands in these examples refer to either the protonated or non-protonated forms of the ligands.)
  • Functionalized aminocarboxylates include ligands that have a combination of amine nitrogen and oxygen donor atoms. Examples include but are not limited to: iminodiacetic acid, 2 , 3-diaminopropionic acid, nitrilotriacetic acid, N,N' -ethylenediamine diacetic acid, N,N,N' -ethylenediamine triacetic acid, hydroxyethylethylenediamine triacetic acid, and N,N' -ethylenediamine bis-hydroxyphenylglycine. (The names for the ligands in these examples refer to either the protonated or non-protonated forms of the ligands.) A series of functionalized aminocarboxylates are disclosed by Bridger et.
  • the preferred ancillary ligands A I functionalized aminocarboxylates that are derivatives of glycine; the most preferred is tricine (tris (hydroxymethyl)methylglycine) .
  • the most preferred technetium radiopharmaceuticals of the present invention are comprised of a hydrazido or diazenido bonding unit and two types of ancillary designated A L I and A L2 , or a diaminedithiol chelator.
  • the second type of ancillary ligands A L are comprised of one or more soft donor atoms selected from the group: phosphine phosphorus, arsine arsenic, imine nitrogen (sp 2 hybridized) , sulfur (sp 2 hybridized) and carbon (sp hybridized); atoms which have p-acid character.
  • Ligands A L2 can be monodentate, bidentate or tridentate, the denticity is defined by the number of donor atoms in the ligand.
  • One of the two donor atoms in a bidentate ligand and one of the three donor atoms i a tridentate ligand must be a soft donor atom.
  • radiopharmaceuticals comprised of one or more ancillary or co-ligands A L are more stable compared to radiopharmaceuticals that are not comprised of one or more ancillary ligands, A L ; that is, they have a minimal number of isomeric forms, the relative ratios of which do not change significantly with time, and that remain substantially intact upon dilution.
  • the ligands A L2 that are comprised of phosphine or arsine donor atoms are trisubstituted phosphines, trisubstituted arsines, tetrasubstituted diphosphines and tetrasubstituted diarsines.
  • the ligands A L that are comprised of imine nitrogen are unsaturated or aromatic nitrogen-containing, 5 or 6-membered heterocycles.
  • the ligands comprised of carbon (sp hybridized) donor atoms are isonitriles, comprised of the moiety CNR, where R is an organic radical.
  • Isonitriles can be synthesized as described in European Patent 0107734 and in U.S. Patent 4,988,827, herein incorporated by reference.
  • Preferred ancillary ligands A L2 are trisubstituted phosphines and unsaturated or aromatic 5 or 6 membered heterocycles .
  • the most preferred ancillary ligands A L are trisubstituted phosphines and unsaturated 5 membered heterocycles.
  • the ancillary ligands A L may be substituted with alkyl, aryl, alkoxy, heterocycle, aralkyl, alkaryl and arylalkaryl groups and may or may not bear functional groups comprised of heteroatoms such as oxygen, nitrogen, phosphorus or sulfur.
  • functional groups include but are not limited to: hydroxyl, carboxyl, carboxamide, nitro, ether, ketone, amino, ammonium, sulfonate, sulfonamide, phosphonate, and phosphonamide.
  • the functional groups may be chosen to alter the lipophilicity and water solubility of the ligands which may affect the biological properties of the radiopharmaceuticals, such as altering the distribution into non-target tissues, cells or fluids, and the mechanism and rate of elimination from the body.
  • Chelators or bonding moieties for therapeutic radiopharmaceuticals are selected to form stable complexes with the radioisotopes that have alpha particle, beta particle, Auger or Coster-Kronig electron emissions , such as 186 Re , 188 Re , 153 Sm, 166 Ho , 177 Lu ,
  • Chelators for rhenium, copper, palladium, platinum, iridium, rhodium, silver and gold isotopes are selected from diaminedithiols, monoamine-monoamidedithiols, triamide-monothiols , monoamine-diamide-monothiols, diaminedioximes, and hydrazines.
  • Chelators for yttrium, bismuth, and the lanthanide isotopes are selected from cyclic and acyclic polyaminocarboxylates such as DTPA, DOTA, D03A, 2-benzyl-DOTA, alpha- (2-phenethyl) 1, 4, 7, 10- tetraazacyclododecane-l-acetic-4 , 7 , 10- tris (methylacetic) cid, 2-benzyl- cyclohexyldiethylenetriaminepentaacetic acid, 2-benzyl- 6-methyl-DTPA, and 6, 6 " -bis [N,N,N" ,N" - tetra(carboxymethyl) aminomethyl) -4' - (3-amino-4- methoxyphenyl) -2 , 2 ' : 6 ' , 2 "-terpyridine .
  • Chelators for magnetic resonance imaging contrast agents are selected to form stable complexes with paramagnetic metal ions, such as Gd(III), Dy(III), Fe(III), and Mn(II), are selected from cyclic and acyclic polyaminocarboxylates such as DTPA, DOTA, D03A, 2-benzyl-DOTA, alpha- (2-phenethyl) 1,4,7,10- tetraazacyclododecane-l-acetic-4 , 7 , 10- tris (methylacetic) acid, 2-benzyl- cyclohexyldiethylenetriaminepentaacetic acid, 2-benzyl- 6-methyl-DTPA, and 6, 6" -bis [N,N,N" ,N" - tetra(carboxymethyl) aminomethyl) -4'- (3-amino-4- methoxyphenyl) -2 , 2 ' : 6 ' , 2 " -terpyridine.
  • the technetium and rhenium radiopharmaceuticals of the present invention comprised of a hydrazido or diazenido bonding unit can be easily prepared by admixing a salt of a radionuclide, a reagent of the present invention, an ancillary ligand A L I, an ancillary ligand A L2 , and a reducing agent, in an aqueous solution at temperatures from 0 to 100 °C.
  • the technetium and rhenium radiopharmaceuticals of the present invention comprised of a tetradentate chelator having two nitrogen and two sulfur atoms can be easily prepared by admixing a salt of a radionuclide, a reagent of the present invention, and a reducing agent, in an aqueous solution at temperatures from 0 to 100 °C.
  • the bonding unit in the reagent of the present invention When the bonding unit in the reagent of the present invention is present as a hydrazone group, then it must first be converted to a hydrazine, which may or may not be protonated, prior to complexation with the metal radionuclide.
  • the conversion of the hydrazone group to the hydrazine can occur either prior to reaction with the radionuclide, in which case the radionuclide and the ancillary or co-ligand or ligands are combined not with the reagent but with a hydrolyzed form of the reagent bearing the chelator or bonding unit, or in the presence of the radionuclide in which case the reagent itself is combined with the radionuclide and the ancillary or co-ligand or ligands. In the latter case, the pH of the reaction mixture must be neutral or acidic.
  • the radiopharmaceuticals of the present invention comprised of a hydrazido or diazenido bonding unit can be prepared by first admixing a salt of a radionuclide, an ancillary ligand A L I, and a reducing agent in an aqueous solution at temperatures from 0 to
  • the radiopharmaceuticals of the present invention comprised of a hydrazido or diazenido bonding unit can be prepared by first admixing a salt of a radionuclide, an ancillary ligand A L I, a reagent of the present invention, and a reducing agent in an aqueous solution at temperatures from 0 to 100 °C to form an intermediate radionuclide complex, and then adding an ancillary ligand A L2 and reacting further at temperatures from 0 to 100 °C.
  • the technetium and rhenium radionuclides are preferably in the chemical form of pertechnetate or perrhenate and a pharmaceutically acceptable cation.
  • the pertechnetate salt form is preferably sodium pertechnetate such as obtained from commercial Tc-99m generators.
  • the amount of pertechnetate used to prepare the radiopharmaceuticals of the present invention can range from 0.1 mCi to 1 Ci, or more preferably from 1 to 200 mCi.
  • the amount of the reagent of the present invention used to prepare the technetium and rhenium radiopharmaceuticals of the present invention can range from 0.01 ⁇ g to 10 mg, or more preferably from 0.5 ⁇ g to 200 ⁇ g. The amount used will be dictated by the amounts of the other reactants and the identity of the radiopharmaceuticals of the present invention to be prepared.
  • the amounts of the ancillary ligands A L I used can range from 0.1 mg to 1 g, or more preferably from 1 mg to 100 mg.
  • the exact amount for a particular radiopharmaceutical is a function of identity of the radiopharmaceuticals of the present invention to be prepared, the procedure used and the amounts and identities of the other reactants. Too large an amount of I will result in the formation of by-products comprised of technetium labeled A L I without a biologically active molecule or by-products comprised of technetium labeled biologically active molecules with the ancillary ligand A L I but without the ancillary ligand A L2 .
  • the amounts of the ancillary ligands A L2 used can range from 0.001 mg to 1 g, or more preferably from 0.01 mg to 10 mg.
  • the exact amount for a particular radiopharmaceutical is a function of the identity of the radiopharmaceuticals of the present invention to be prepared, the procedure used and the amounts and identities of the other reactants. Too large an amount of A 2 will result in the formation of by-products comprised of technetium labeled L without a biologically active molecule or by-products comprised of technetium labeled biologically active molecules with the ancillary ligand A L2 but without the ancillary ligand A L I.
  • the reagent bears one or more substituents that are comprised of a soft donor atom, as defined above, at least a ten-fold molar excess of the ancillary ligand A L to the reagent of formula 2 is required to prevent the substituent from interfering with the coordination of the ancillary ligand A 2 to the metal radionuclide.
  • Suitable reducing agents for the synthesis of the radiopharmaceuticals of the present invention include stannous salts, dithionite or bisulfite salts, borohydride salts, and formamidinesulfinic acid, wherein the salts are of any pharmaceutically acceptable form.
  • the preferred reducing agent is a stannous salt.
  • the amount of a reducing agent used can range from 0.001 mg to 10 mg, or more preferably from 0.005 mg to 1 mg.
  • Radiopharmaceuticals comprised of a hydrazido or diazenido bonding unit will depend on the identity of the reagent of the present invention used, the identity of any ancillary ligand A L I, the identity of any ancillary ligand A L2 , and the identity of the radionuclide.
  • Radiopharmaceuticals comprised of a hydrazido or diazenido bonding unit synthesized using concentrations of reagents of ⁇ 100 ⁇ g/mL, will be comprised of one hydrazido or diazenido group.
  • Those synthesized using >1 mg/mL concentrations will be comprised of two hydrazido or diazenido groups from two reagent molecules.
  • the biologically active molecule can be injected and not result in undesired side-effects, such as chemical toxicity, interference with a biological process or an altered biodistribution of the radiopharmaceutical. Therefore, the radiopharmaceuticals which require higher concentrations of the reagents comprised in part of the biologically active molecule, will have to be diluted or purified after synthesis to avoid such side-effects.
  • the identities and amounts used of the ancillary ligands A L I and A L2 will determine the values of the variables y and z.
  • the values of y and z can independently be an integer from 1 to 2. In combination, the values of y and z will result in a technetium coordination sphere that is made up of at least five and no more than seven donor atoms .
  • Z can be an integer from 1 to 2; for bidentate or tridentate ancillary ligands A L2 , z is 1.
  • the preferred combination for monodentate ligands is y equal to 1 or 2 and z equal to 1.
  • the preferred combination for bidentate or tridentate ligands is y equal to 1 and z equal to 1.
  • the indium, copper, gallium, silver, palladium, rhodium, gold, platinum, bismuth, yttrium and lanthanide radiopharmaceuticals of the present invention can be easily prepared by admixing a salt of a radionuclide and a reagent of the present invention, in an aqueous solution at temperatures from 0 to 100 °C .
  • These radionuclides are typically obtained as a dilute aqueous solution in a mineral acid, such as hydrochloric, nitric or sulfuric acid.
  • the radionuclides are combined with from one to about one thousand equivalents of the reagents of the present invention dissolved in aqueous solution.
  • a buffer is typically used to maintain the pH of the reaction mixture between 3 and 10.
  • the gadolinium, dysprosium, iron and manganese metallopharmaceuticals of the present invention can be easily prepared by admixing a salt of the paramagnetic metal ion and a reagent of the present invention, in an aqueous solution at temperatures from 0 to 100 °C.
  • These paramagnetic metal ions are typically obtained as a dilute aqueous solution in a mineral acid, such as hydrochloric, nitric or sulfuric acid.
  • the paramagnetic metal ions are combined with from one to about one thousand equivalents of the reagents of the present invention dissolved in aqueous solution.
  • a buffer is typically used to maintain the pH of the reaction mixture between 3 and 10.
  • the total time of preparation will vary depending on the identity of the metal ion, the identities and amounts of the reactants and the procedure used for the preparation.
  • the preparations may be complete, resulting in > 80% yield of the radiopharmaceutical, in 1 minute or may require more time. If higher purity metallopharmaceuticals are needed or desired, the products can be purified by any of a number of techniques well known to those skilled in the art such as liquid chromatography, solid phase extraction, solvent extraction, dialysis or ultrafiltration.
  • Buffers useful in the preparation of metallopharmaceuticals and in diagnostic kits useful for the preparation of said radiopharmaceuticals include but are not limited to phosphate, citrate, sulfosalicylate, and acetate. A more complete list can be found in the United States Pharmacopeia.
  • Lyophilization aids useful in the preparation of diagnostic kits useful for the preparation of radiopharmaceuticals include but are not limited to mannitol, lactose, sorbitol, dextran, Ficoll, and polyvinylpyrrolidine (PVP) .
  • Stabilization aids useful in the preparation of metallopharmaceuticals and in diagnostic kits useful for the preparation of radiopharmaceuticals include but are not limited to ascorbic acid, cysteine, monothioglycerol, sodium bisulfite, sodium metabisulfite, gentisic acid, and inositol.
  • Solubilization aids useful in the preparation of metallopharmaceuticals and in diagnostic kits useful for the preparation of radiopharmaceuticals include but are not limited to ethanol, glycerin, polyethylene glycol, propylene glycol, polyoxyethylene sorbitan monooleate, sorbitan monoloeate, polysorbates, poly(oxyethylene)poly(oxypropylene) poly(oxyethylene) block copolymers (Pluronics) and lecithin.
  • Preferred solubilizing aids are polyethylene glycol, and Pluronics .
  • Bacteriostats useful in the preparation of metallopharmaceuticals and in diagnostic kits useful for the preparation of radiopharmaceuticals include but are not limited to benzyl alcohol, benzalkonium chloride, chlorbutanol , and methyl, propyl or butyl paraben.
  • a component in a diagnostic kit can also serve more than one function.
  • a reducing agent can also serve as a stabilization aid, a buffer can also serve as a transfer ligand, a lyophilization aid can also serve as a transfer, ancillary or co-ligand and so forth.
  • the diagnostic radiopharmaceuticals are administered by intravenous injection, usually in saline solution, at a dose of 1 to 100 mCi per 70 kg body weight, or preferably at a dose of 5 to 50 mCi . Imaging is performed using known procedures.
  • the therapeutic radiopharmaceuticals are administered by intravenous injection, usually in saline solution, at a dose of 0.1 to 100 mCi per 70 kg body weight, or preferably at a dose of 0.5 to 5 mCi per ' 70 kg body weight.
  • the magnetic resonance imaging contrast agents of the present invention may be used in a similar manner as other MRI agents as described in U.S. Patent 5,155,215; U.S. Patent 5,087,440; Margerstadt et al . , Magn. Reson. Med., 1986, 3, 808; Runge et al . , Radiology, 1988, 166, 835; and Bousquet et al . , Radiology, 1988, 166, 693.
  • sterile aqueous solutions of the contrast agents are administered to a patient intravenously in dosages ranging from 0.01 to 1.0 mmoles per kg body weight.
  • compositions of the present invention should generally have a heavy atom concentration of 1 mM to 5 M, preferably 0.1 M to 2 M.
  • Dosages, administered by intravenous injection will typically range from 0.5 mmol/kg to 1.5 mmol/kg, preferably 0.8 mmol/kg to 1.2 mmol/kg. Imaging is performed using known techniques, preferably X-ray computed tomography.
  • the ultrasound contrast agents of the present invention are administered by intravenous injection in an amount of 10 to 30 ⁇ L of the echogenic gas per kg body weight or by infusion at a rate of approximately 3 ⁇ L/kg/min. Imaging is performed using known techniques of sonography.
  • HBTU 2- (lH-Benzotriazol-1-yl) -1,1,3, 3-tetramethyluronium hexafluorophosphate
  • TBTU 2-(lH-Benzotriazol-1-yl) -1,1,3, 3-tetramethyluronium hexafluorophosphate
  • NMM N-methylmorpholine
  • Abu D-2-aminobutyric acid
  • TPTS tris (3-sulfonatophenyl) phosphine trisodium salt
  • TPDS Bis (3-sulfonatophenyl) phenyIphosphine disodium salt
  • TPMS TCI America, Inc. Tricine was obtained from Research Organics, Inc. Technetium-99m- pertechnetate ( 99m Tc ⁇ 4 ⁇ ) was obtained from a DuPont
  • In-111-chloride (Indichlor®) was obtained from Amersham Medi-Physics, Inc. Sm-153-chloride and Lutetium-177-chloride were obtained from the University of Missouri Research Reactor (MURR) . Yttrium-90 chloride was obtained from the Pacific Northwest Research Laboratories. Dimethylformamide (DMF) , ethyl acetate, chloroform
  • HCI Hydraulic acid
  • DCM dichloromethane
  • HOAc acetic acid
  • TFA trifluoroacetic acid
  • ethyl ether ethyl ether
  • triethylamine triethylamine
  • acetone acetone
  • magnesium sulfate magnesium sulfate
  • Cyclic Peptides The appropriately protected cyclic peptides, described in the Examples, were prepared by manual solid phase peptide synthesis using Boc-teabag chemistry (Houghton, 1985) on a p-nitrobenzophenone oxime solid support (DeGrado, 1982, Scarr and Findeis, 1990).
  • the 5.0 cm x 5.0 cm teabags were made from 0.75 mm mesh polypropylene filters (Spectra Filters) and filled with 0.5 g (or 1 g) of the oxime resin.
  • the coupling and deprotection steps were carried out in a polypropylene reactor using a table-top shaker for agitation.
  • Synthesis of the protected pentapeptide-resin intermediate was achieved by first coupling Boc-Gly-OH to the oxime' resin (substitution 0.69 mmol/g or 0.95 mmol/g) . Attachment of Boc-Gly-OH onto the oxime resin was achieved by using five equivalents each of the amino acid, HBTU and diisopropylethylamme (DIPEA) in DMF. Coupling of the first amino acid generally occurred over 2-3 days. After thorough washing, substitution levels were determined using the picric acid assay (Stewart and Martin) . Unreacted oxime groups on the resin were then capped with a solution of DIPEA and trimethylacetyl chloride in DMF.
  • DIPEA diisopropylethylamme
  • the boc-group was deprotected using 50% or 25% TFA in DCM (30 min) . Coupling of the other protected boc-amino acids were performed in a similar manner by overnight shaking (1-2 days), and the coupling yields for each newly added amino acid was determined using the picric acid assay.
  • Examples were also prepared by automated solid phase peptide synthesis using Fmoc chemistry on an Advanced ChemTech Model 90 Synthesizer and using HMPB-BHA resin as the solid support. Synthesis of the protected pentapeptide-resin intermediates was achieved by coupling (for 3 h) the Fmoc-amino acids sequentially to the commercially available (Novabiochem) Fmoc-Gly-HMPB- BHA resin (usually 2 g, substitution 0.47 to 0.60 mmol/g) by using three to five equivalents each of the amino acid, HBTU, HOBt and diisopropylethylamme (DIPEA) in DMF.
  • DIPEA diisopropylethylamme
  • the Fmoc-group was deprotected using 20% piperidine in DMF (30 min) .
  • the peptides were cleaved from the HMPB-BHA resin using a solution of 1% TFA/DCM and collecting the peptide solutions in a solution of pyridine in methanol (1:10) .
  • the linear protected ; ⁇ .__ peptides were isolated by removing the solvents and reagents in vacuo and triturating the crude residue in diethyl ether.
  • Boc-HomoLys (Tfa) -OH and Boc-Cys (2-N-Tfa- aminoethyl) -OH are prepared via the reaction of Boc- HomoLys-OH and Boc-Cys (2 -aminoethyl) -OH, respectively, with ethyl thioltrifluoroacetate in Aq. NaOH, and purified by recrystallization from ethanol.
  • Boc-Orn (d-N-l-Tos-2-Imidazolinyl)
  • l-tosyl-2- methylthio-2-imidazoline (12 mmol, (which in turn is prepared from the reaction of the commercially available 2-methylthio-2-imidazoline hydriodide and p- toluenesulfonic anhydride in methylene chloride (0 »C to RT) in the presence of triethylamine) ) , and diisopropylethylamme (12 mmol) is stirred at reflux, overnight. The volatiles are removed and the desired product isolated by chromatography.
  • Dap (b- (l-Tos-2-benzimidazolylacetyl)
  • l-Tos-2-benzimidazolylacetic acid 10 mmol, prepared using tosyl chloride and standard reported conditions
  • isobutyl chloroformate 10 mmol
  • Boc-Orn-OH 10 mmol
  • N-methylmorpholine 20 mmol
  • the reaction mixture is stirred overnight at room temperature, the volatiles removed in vacuo, and the product is isolated by chromatography.
  • Boc-Orn-OMe is used and the product isolated is treated with aqueous LiOH to obtain the acid.
  • the N-terminus Boc- protecting group of the peptide sequence Boc-Asp (OBzl) -D-Tyr (N-Cbz-aminopropyl) -Val- Arg (Tos) -Gly-Oxime resin was removed using standard deprotection (25% TFA in CH2CI2) • After eight washes with DCM, the resin was treated with 10% DIEA/DCM (2 x 10 min.) . The resin was subsequently washed with DCM (x 5) and dried under high vacuum. The resin (1.7474 g, 0.55 mmol/g) was then suspended in dimethylformamide (15 mL) .
  • Part B Preparation of cyclo ⁇ Arg-Gly-Asp-D-Tyr (3- aminopropyl) -Val ⁇ Trifluoroacetic acid salt.
  • Cyclo ⁇ Arg (Tos) -Gly-Asp (OBzl) -D-Tyr (N-Cbz-3- aminopropyl ) -Val ⁇ (0.150 g, 0.146 mmol) was dissolved in trifluoroacetic acid (0.6 mL) and cooled to -10 »C.
  • Trifluoromethanesulfonic acid (0.5 L) was added dropwise, maintaining the temperature at -10 »C.
  • N-(3-(2-(2-(3- Aminopropoxy) ethoxy) ethoxy) propyl) (tert-butoxy) formamide (1.5 g, 4.68 mmol) was added to DMF (15 mL) .
  • pyridine 15 mL
  • succinic anhydride (0.47 g, 4.68 mmol) were added, followed by dimethylaminopyridine (62 mL, 0.468 ⁇ mol) .
  • the reaction mixture was stirred overnight at 100 »C.
  • the mixture was concentrated under high vacuum and the residue was brought up in water, acidified to pH 2.5 with IN HCI, and extracted with ethyl acetate (3x) .
  • the combined organic extracts were dried over MgS04 and filtered.
  • the filtrate was concentrated in vacuo to provide 1.24 g of an oil product (63%) .
  • the desired product was used without further purification.
  • NMR (CDCI3) 3.67-3.45 (m,
  • Part B Preparation of 3- (N- (3- (2- (2- (3- ( (tert-butoxy) - carbonylamino) propoxy) ethoxy) ethoxy) propyl) carbamoyl) propanoic acid succinimide ester
  • Cyclo ⁇ Arg-Gly-Asp-D-Tyr (3-(3-(N-(3-(2-(2-(3-(( tert- butoxy) -carbonylamino) propoxy) ethoxy) ethoxy) propyl) - carbamoyl) -propanamido) propyl) -Val ⁇ (6.0 mg, 0.00515 mmol) was dissolved in methylene chloride (1 mL) and trifluoroacetic acid (1 mL) was added. The solution stirred for 2 h and then concentrated to an oil under high vacuum.
  • Boc-Glu (cyclo ⁇ D-Tyr (3 -aminopropyl) -Val-Arg-Gly- Asp ⁇ ) -cyclo ⁇ D-Tyr (3 -aminopropyl) -Val-Arg-Gly-Asp ⁇ (0.035 g, 0.0232 mmol) was dissolved in methylene chloride (1 mL) . Trifluoroacetic acid (1 mL) was added, and the reaction mixture was stirred for 2 h, concentrated to an oil under high vacuum and triturated with ether. The product obtained was filtered, washed with diethyl ether, and dried under high vacuum to give 30.7 mg (76%) of the desired product.
  • ESMS Calcd. for C63H95N19O18 ,
  • the N-terminus Boc-protecting group of the peptide sequence Boc-Asp (OBzl) -D-Tyr (Bzl) -Lys(Z) -Arg (Tos) -Gly- oxime resin was removed using standard deprotection (25% TFA in CH2CI2) • After eight washes with DCM, the resin was treated with 10% DIEA/DCM (2 x 10 min.). The resin was subsequently washed with DCM (x 5) and dried under high vacuum. The resin (1.8711 g, 0.44 mmol/g) was then suspended in DMF (15 mL) .
  • Cyclo ⁇ Arg (Tos) -Gly-Asp (OBzl) -D-Tyr (Bzl) -Lys (Cbz) ⁇ (0.200 g, 0.184 mmol) was dissolved in trifluoroacetic acid (0.6 mL) and cooled to -10 »C.
  • Trifluoromethanesulfonic acid 0.5 mL was added dropwise, maintaining the temperature at -10 »C.
  • Anisole (0.1 mL) was added and the reaction mixture was stirred at -10 »C for 3 h. Diethyl ether was added, the reaction was cooled to -50 »C, and stirred for 1 h.
  • the N-terminus Boc- protecting group of the peptide sequence Boc-Asp (OBzl) -D-Phe-Lys (Z) -Arg (Tos) -Gly-Oxime resin was removed using standard deprotection (25% TFA in CH2CI2) • After eight washes with DCM, the resin was treated with 10% DIEA/DCM (2 x 10 min.). The resin was subsequently washed with DCM (x 5) and dried under high vacuum. The resin (1.7053 g, 0.44 mmol/g) was then suspended in dimethylformamide (15 mL) . Glacial acetic acid (43.0 ⁇ L, 0.750 mmol) was added, and the reaction was heated to 60 »C for 72 h.
  • the peptide Asp (OtBu) -D-Nal-Lys (Boc) -Arg (Mtr) -Gly was obtained by automated solid phase peptide synthesis using Fmoc chemistry.
  • a 100 mL round bottom flask was charged with HBTU (349 mg, 0.92 mmol) and DMF (10 mL) .
  • the solution was stirred at 60 »C for 5 min.
  • Cyclo ⁇ Arg-Gly-Asp-D-Nal-Lys ⁇ TFA salt (0.056 g, 0.064 mmol) was dissolved in DMF (2 mL) . Triethylamine (27 ⁇ L, 0.19 mmol) was added, and after 5 min of stirring 2- [ [ [5- [ [ (2 , 5-dioxo-l- pyrrolidinyl) oxy] carbonyl] -2-pyridinyl] -hydrazono] - methyl] -benzenesulfonic acid, monosodium salt (0.039 g, 0.089 mmol) was added. The reaction mixture was stirred overnight, under nitrogen, and then concentrated to an oil under high vacuum.
  • Boc-protecting group of the peptide sequence Boc-Arg(Tos) -D-Val-D-Tyr (N-Cbz-aminopropyl) -D- Asp (OBzl) -Gly-Oxime resin was removed using standard deprotection (50% TFA in CH2CI2) • After washing with
  • the N-terminus Boc- protecting group of the peptide sequence Boc-Arg (Tos) -D-Lys (Cbz) -D-Phe-D-Asp (OBzl) -Gly- Oxime resin was removed using standard deprotection (25% TFA in CH2CI2) . After eight washes with DCM, the resin was treated with 10% DIEA/DCM (2 x 10 min.) . The resin was subsequently washed with DCM (x 5) and dried under high vacuum. The resin (1.93 g, 0.44 mmol/g) was then suspended in dimethylformamide (15 mL) . Glacial acetic acid (77 ⁇ L) was added, and the reaction was heated to 60 «C for 72 h.
  • the N-terminus Boc- protecting group of the peptide sequence Boc-Arg (Tos) -D-Phe-D-Lys (Cbz) -D-Asp(OBzl) -Gly- Oxime resin was removed using standard deprotection (25% TFA in CH2CI2) • After eight washes with DCM, the resin was treated with 10% DIEA/DCM (2 x 10 min.) . The resin was subsequently washed with DCM (x 5) and dried under high vacuum. The resin (1.5 g, 0.44 mmol/g) was then suspended in dimethylformamide (12 mL) . Glacial acetic acid (61 ⁇ L) was added, and the reaction was heated to 60 - C for 72 h.
  • the N-terminus Boc-protecting group of the peptide sequence Boc-Asp (OBzl) -ATA-D-Lys (Z) -N-Me-Arg (Tos) -Gly- Oxime resin was removed using standard deprotection (50% TFA in CH2CI2) • After washing with DCM (8x) , the resin was treated with 10% DIEA/DCM (2 x 10 min) . The resin was washed with DCM (5x) and dried under high vacuum overnight. The resin (1.24 g, 0.39 mmol/g) was then suspended in DMF (12 mL) . Glacial acetic acid (67 mL, 1.16 mmol) was added and the reaction mixture was heated at 50 »C for 72 h.
  • the peptide Asp (OtBu) -D-Phe-Lys (Boc) -Cit-Gly was obtained by automated solid phase peptide synthesis using Fmoc chemistry (see general procedure) .
  • a 100 mL round bottom flask was charged with HBTU (271 mg, 0.71 mmol) and DMF (10 mL) .
  • the solution was stirred at 60 •C for 5 min.
  • Part A Preparation of cyclo ⁇ Orn (d-N-l-Tos-2- Imidazolinyl) -Gly-Asp (OBzl) -D-Tyr (N-Cbz-3 -aminopropyl) Val ⁇
  • Boc- protecting group of the peptide sequence Boc-Asp (OBzl) -D-Tyr (N-Cbz-aminopropyl) -Val- Orn(d-N-l-Tos-2-Imidazolinyl) -Gly-Oxime resin is removed using standard deprotection (25% TFA in CH2CI2).
  • the resin is treated with 10% DIEA/DCM (2 x 10 min.). The resin is subsequently washed with DCM (x 5) and dried under high vacuum.
  • the resin (1.75 g, 0.55 mmol/g) is then suspended in dimethylformamide (15 mL) . Glacial acetic acid (55.0 ⁇ L, 0.961 mmol) is added, and the reaction mixture is heated at 50 »C for 72 h.
  • the resin is filtered, and washed with DMF (2 x 10 mL) . The filtrate is concentrated to an oil under high vacuum. The resulting oil is triturated with ethyl acetate. The solid is filtered, washed with ethyl acetate, and is dried under high vacuum to obtain the desired product.
  • Part B Preparation of cyclo ⁇ Orn (d-N-2-Imidazolinyl) - Gly-Asp-D-Tyr (3 -aminopropyl) -Val ⁇ . Trifluoroacetic acid salt.
  • Part A Preparation of cyclo ⁇ Lys (Tfa) -Gly-Asp (OBzl) -D- Tyr (N-Cbz-3-aminopropyl) -Val ⁇
  • Boc- protecting group of the peptide sequence Boc-Asp (OBzl) -D-Tyr (N-Cbz-aminopropyl) -Val- Lys (Tfa) -Gly-Oxime resin is removed using standard deprotection (25% TFA in CH2CI2) • After eight washes with DCM, the resin is treated with 10% DIEA/DCM (2 x 10 min.) . The resin is subsequently washed with DCM (x 5) and dried under high vacuum.
  • the resin (1.75 g, 0.55 mmol/g) is then suspended in dimethylformamide (15 mL) . Glacial acetic acid (55.0 ⁇ L, 0.961 mmol) is added, and the reaction mixture is heated at 50 «C for 72 h. The resin is filtered, and washed with DMF (2 x 10 mL) . The filtrate is concentrated to an oil under high vacuum. The resulting oil is triturated with ethyl acetate. The solid thus obtained is filtered, washed with ethyl acetate, and is dried under high vacuum to obtain the desired product.
  • Part B Preparation of cyclo ⁇ Lys (Tfa) -Gly-Asp-D-Tyr (3- aminopropyl) -Val ⁇ Trifluoroacetic acid salt.
  • Cyclo ⁇ Lys (Tfa) -Gly-Asp (OBzl) -D-Tyr (N-Cbz-3- aminopropyl) -Val ⁇ (0.146 mmol) is dissolved in trifluoroacetic acid (0.6 mL) and cooled to -10 »C.
  • Trifluoromethanesulfonic acid (0.5 L) is added dropwise, maintaining the temperature at -10 *C.
  • Part A Preparation of cyclo ⁇ Cys (2-N-Tfa-aminoethyl) - Gly-Asp (OBzl) -D-Tyr (N-Cbz-3-aminopropyl) -Val ⁇
  • Boc- protecting group of the peptide sequence Boc-Asp (OBzl) -D-Tyr (N-Cbz-aminopropyl) -Val- Cys (2-N-Tfa-aminoethyl) -Gly-Oxime resin is removed using standard deprotection (25% TFA in CH2CI2) • After eight washes with DCM, the resin is treated with 10% DIEA/DCM (2 x 10 min.) .
  • the resin is subsequently washed with DCM (x 5) and dried under high vacuum.
  • the resin (1.75 g, 0.55 mmol/g) is then suspended in dimethylformamide (15 mL) .
  • Glacial acetic acid (55.0 ⁇ L, 0.961 mmol) is added, and the reaction mixture is heated at 50 »C for 72 h.
  • the resin is filtered, and washed with DMF (2 x 10 mL) .
  • the filtrate is concentrated to an oil under high vacuum.
  • the resulting oil is triturated with ethyl acetate.
  • the solid thus obtained is filtered, washed with ethyl acetate, and dried under high vacuum to obtain the desired product.
  • Part B Preparation of cyclo ⁇ Cys (2-N-Tfa-aminoethyl ) - Gly-Asp-D-Tyr (3-aminopropyl) -Val ⁇ . Trifluoroacetic acid salt.
  • Cyclo ⁇ Cys (2-N-Tfa-aminoethyl) -Gly-Asp (OBzl) -D- Tyr (N-Cbz-3-aminopropyl) -Val ⁇ (0.146 mmol) is dissolved in trifluoroacetic acid (0.6 mL) and cooled to -10 »C.
  • Trifluoromethanesulfonic acid 0.5 mL is added dropwise, maintaining the temperature at -10 »C.
  • Anisole 0.1 mL
  • Diethyl ether is added, the reaction mixture cooled to -35 «C and then stirred for 30 min.
  • Part A Preparation of cyclo ⁇ HomoLys (Tfa) -Gly-Asp (OBzl) - D-Tyr (N-Cbz-3-aminopropyl) -Val ⁇
  • the N-terminus Boc- protecting group of the peptide sequence Boc-Asp (OBzl) -D-Tyr (N-Cbz-aminopropyl) -Val- HomoLys (Tfa) -Gly-Oxime resin is removed using standard deprotection (25% TFA in CH2CI2). After eight washes with DCM, the resin is treated with 10% DIEA/DCM (2 x 10 min.) .
  • the resin is subsequently washed with DCM (x 5) and dried under high vacuum.
  • the resin (1.75 g, 0.55 mmol/g) is then suspended in dimethylformamide (15 mL) .
  • Glacial acetic acid (55.0 ⁇ L, 0.961 mmol) is added, and the reaction mixture is heated at 50 »C for 72 h.
  • the resin is filtered, and washed with DMF (2 x 10 mL) .
  • the filtrate is concentrated to an oil under high vacuum.
  • the resulting oil is triturated with ethyl acetate.
  • the solid thus obtained is filtered, washed with ethyl acetate, and dried under high vacuum to obtain the desired product.
  • Part B Preparation of cyclo ⁇ HomoLys (Tfa) -Gly-Asp-D- Tyr (3-aminopropyl) -Val ⁇ , Trifluoroacetic acid salt.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Quinoline Compounds (AREA)
  • Radiation-Therapy Devices (AREA)

Abstract

L'invention concerne des composés de formule (I):(Q)d-Ln-Ch, (I):utiles pour le diagnostic et le traitement de cancer en thérapie de combinaison chez un patient. Elle concerne des composés utiles dans le traitement de l'arthrite rhumatoïde. Les produits pharmaceutiques sont constitués d'une entité de ciblage qui se lie à un récepteur qui est régulé positivement durant l'angiogénèse, éventuellement d'un groupe de liaison, et d'un radio-isotope efficace sur le plan thérapeutique ou d'une entité à imagerie efficace sur le plan du diagnostic.
PCT/US2001/020108 2000-06-21 2001-06-21 Produits pharmaceutiques pour l'imagerie de troubles angiogeniques WO2001097860A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU2001268710A AU2001268710A1 (en) 2000-06-21 2001-06-21 Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
EP01946697A EP1311302A2 (fr) 2000-06-21 2001-06-21 Produits pharmaceutiques pour l'imagerie de troubles angiogeniques
JP2002503343A JP2005538030A (ja) 2000-06-21 2001-06-21 組み合わせ療法での使用のための血管新生障害の画像診断用医薬
CA002413328A CA2413328A1 (fr) 2000-06-21 2001-06-21 Produits pharmaceutiques pour l'imagerie de troubles angiogeniques

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21320600P 2000-06-21 2000-06-21
US60/213,206 2000-06-21

Publications (2)

Publication Number Publication Date
WO2001097860A2 true WO2001097860A2 (fr) 2001-12-27
WO2001097860A3 WO2001097860A3 (fr) 2003-02-27

Family

ID=22794144

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/020108 WO2001097860A2 (fr) 2000-06-21 2001-06-21 Produits pharmaceutiques pour l'imagerie de troubles angiogeniques

Country Status (5)

Country Link
EP (1) EP1311302A2 (fr)
JP (1) JP2005538030A (fr)
AU (1) AU2001268710A1 (fr)
CA (1) CA2413328A1 (fr)
WO (1) WO2001097860A2 (fr)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001097848A2 (fr) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Agents pharmaceutiques antagonistes du recepteur de vitronectine, a utiliser en polytherapie
WO2001097861A2 (fr) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Agents pharmaceutiques antagonistes du recepteur de la vitronectine destines a etre utilises dans une therapie combinee
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6683163B2 (en) 1998-12-18 2004-01-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
EP1401506A2 (fr) * 2001-05-31 2004-03-31 Miravant Pharmaceuticals, Inc. Agents de photosensibilisation tetrapyrroliques metalliques destines a la therapie photodynamique
US7018611B2 (en) 1998-12-18 2006-03-28 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
JP2009161549A (ja) * 2002-03-01 2009-07-23 Dyax Corp Ｋｄｒおよびｖｅｇｆ／ｋｄｒ結合ペプチドならびに診断および治療におけるその使用
US8030338B2 (en) 2007-01-23 2011-10-04 Pola Pharma Inc. Method for producing 2-nitroimidazole derivative
US9056138B2 (en) 2002-03-01 2015-06-16 Bracco Suisse Sa Multivalent constructs for therapeutic and diagnostic applications
US9629934B2 (en) 2002-03-01 2017-04-25 Dyax Corp. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
KR101769911B1 (ko) 2015-11-09 2017-08-21 포항공과대학교 산학협력단 신규한 항암제로서 Skp2 저해제
US9957293B2 (en) 2006-08-23 2018-05-01 Yeda Research And Development Company Ltd. Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
US10137209B2 (en) 2015-06-04 2018-11-27 Bayer Pharma Aktiengesellschaft Gadolinium chelate compounds for use in magnetic resonance imaging
US11103483B2 (en) 2010-01-28 2021-08-31 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US11814369B2 (en) 2016-11-28 2023-11-14 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
US11944690B2 (en) 2018-11-23 2024-04-02 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7794693B2 (en) 2002-03-01 2010-09-14 Bracco International B.V. Targeting vector-phospholipid conjugates
US8623822B2 (en) 2002-03-01 2014-01-07 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013329A1 (fr) * 1997-09-10 1999-03-18 The Burnham Institute Procedes relatifs a l'identification de molecules capables de rallier des systemes vasculaires angiogeniques dans les tumeurs
WO1999058162A2 (fr) * 1998-03-31 1999-11-18 Du Pont Pharmaceuticals Company Produits pharmaceutiques pour l'imagerie de troubles angiogenes
WO2002004030A2 (fr) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Compositions radiopharmaceutiques stables et procedes de fabrication de ces compositions

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999013329A1 (fr) * 1997-09-10 1999-03-18 The Burnham Institute Procedes relatifs a l'identification de molecules capables de rallier des systemes vasculaires angiogeniques dans les tumeurs
WO1999058162A2 (fr) * 1998-03-31 1999-11-18 Du Pont Pharmaceuticals Company Produits pharmaceutiques pour l'imagerie de troubles angiogenes
WO2002004030A2 (fr) * 2000-07-06 2002-01-17 Bristol-Myers Squibb Pharma Company Compositions radiopharmaceutiques stables et procedes de fabrication de ces compositions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"CILENGITIDE//ONCOLYTIC ANGIOGENESIS INHIBITOR INTEGRIN ALPHAVBETA3,ALPHAVBETA5 ANTAGONIST" DRUGS OF THE FUTURE, BARCELONA, ES, vol. 7, no. 25, 2000, pages 674-678, XP008002380 ISSN: 0377-8282 *
BURKE P A ET AL: "COMBINED MODALITY RADIOIMMUNOTHERAPY//PROMISE AND PERIL" CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. SUPPL. 4, no. 94, 15 February 2002 (2002-02-15), pages 1320-1331, XP008001988 ISSN: 0008-543X *
DENARDO S J ET AL: "NEOVASCULAR TARGETING WITH CYCLIC RGD PEPTIDE (CRGDF-ACHA) TO ENHANCE DELIVERY OF RADIOIMMUNOTHERAPY" CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, LIEBERT, US, vol. 15, no. 1, February 2000 (2000-02), pages 71-79, XP000925000 *
LIU S ET AL: "90Y AND 177LU LABELING OF A DOTA-CONJUGATED VITRONECTIN RECEPTOR ANTAGONIST USEFUL FOR TUMOR THERAPY" BIOCONJUGATE CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 4, no. 12, July 2001 (2001-07), pages 559-568, XP001066363 ISSN: 1043-1802 *
WAES1 VAN C ET AL: "EFFECTS OF THE NOVEL ALPHAV INTEGRIN ANTAGONIST SM256 AND CIS-PLATINUM ON GROWTH OF MURINE SQUAMOUS CELL CARCINOMA PAM LY8" INTERNATIONAL JOURNAL OF ONCOLOGY, EDITORIAL ACADEMY OF THE INTERNATIONAL JOURNAL OF ONCOLOGY,, GR, vol. 16, no. 6, 2000, pages 1189-1195, XP000925238 ISSN: 1019-6439 *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569402B1 (en) 1998-12-18 2003-05-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6683163B2 (en) 1998-12-18 2004-01-27 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6689337B2 (en) 1998-12-18 2004-02-10 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US6743412B2 (en) 1998-12-18 2004-06-01 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US7018611B2 (en) 1998-12-18 2006-03-28 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
US7090828B2 (en) 1998-12-18 2006-08-15 Bristol-Myers Squibb Pharma Company Vitronectin receptor antagonist pharmaceuticals
WO2001097848A2 (fr) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Agents pharmaceutiques antagonistes du recepteur de vitronectine, a utiliser en polytherapie
WO2001097861A2 (fr) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company Agents pharmaceutiques antagonistes du recepteur de la vitronectine destines a etre utilises dans une therapie combinee
WO2001097861A3 (fr) * 2000-06-21 2003-02-27 Bristol Myers Squibb Pharma Co Agents pharmaceutiques antagonistes du recepteur de la vitronectine destines a etre utilises dans une therapie combinee
WO2001097848A3 (fr) * 2000-06-21 2003-03-13 Bristol Myers Squibb Pharma Co Agents pharmaceutiques antagonistes du recepteur de vitronectine, a utiliser en polytherapie
EP1401506A2 (fr) * 2001-05-31 2004-03-31 Miravant Pharmaceuticals, Inc. Agents de photosensibilisation tetrapyrroliques metalliques destines a la therapie photodynamique
EP1401506A4 (fr) * 2001-05-31 2005-02-16 Miravant Pharm Inc Agents de photosensibilisation tetrapyrroliques metalliques destines a la therapie photodynamique
JP2009161549A (ja) * 2002-03-01 2009-07-23 Dyax Corp Ｋｄｒおよびｖｅｇｆ／ｋｄｒ結合ペプチドならびに診断および治療におけるその使用
US9056138B2 (en) 2002-03-01 2015-06-16 Bracco Suisse Sa Multivalent constructs for therapeutic and diagnostic applications
US9629934B2 (en) 2002-03-01 2017-04-25 Dyax Corp. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9957293B2 (en) 2006-08-23 2018-05-01 Yeda Research And Development Company Ltd. Conjugates of RGD peptides and porphyrin or (bacterio)chlorophyll photosynthesizers and their uses
US10689415B2 (en) 2006-08-23 2020-06-23 Yeda Research And Development Co. Ltd. Conjugates of RGD peptides and (bacterio)chlorophyll photosensitizers
US8030338B2 (en) 2007-01-23 2011-10-04 Pola Pharma Inc. Method for producing 2-nitroimidazole derivative
US11103483B2 (en) 2010-01-28 2021-08-31 Eagle Pharmaceuticals, Inc. Formulations of bendamustine
US11872214B2 (en) 2010-01-28 2024-01-16 Eagle Pharmaceuticals, Inc. Formulations of Bendamustine
US11491245B2 (en) 2015-06-04 2022-11-08 Bayer Pharma Aktiengesellschaft Gadolinium chelate compounds for use in magnetic resonance imaging
US10722601B2 (en) 2015-06-04 2020-07-28 Bayer Pharma Aktiengesellschaft Gadolinium chelate compounds for use in magnetic resonance imaging
US10137209B2 (en) 2015-06-04 2018-11-27 Bayer Pharma Aktiengesellschaft Gadolinium chelate compounds for use in magnetic resonance imaging
KR101769911B1 (ko) 2015-11-09 2017-08-21 포항공과대학교 산학협력단 신규한 항암제로서 Skp2 저해제
US11814369B2 (en) 2016-11-28 2023-11-14 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
US11944690B2 (en) 2018-11-23 2024-04-02 Bayer Aktiengesellschaft Formulation of contrast media and process of preparation thereof

Also Published As

Publication number Publication date
AU2001268710A1 (en) 2002-01-02
EP1311302A2 (fr) 2003-05-21
JP2005538030A (ja) 2005-12-15
WO2001097860A3 (fr) 2003-02-27
CA2413328A1 (fr) 2001-12-27

Similar Documents

Publication Publication Date Title
US6537520B1 (en) Pharmaceuticals for the imaging of angiogenic disorders
EP1068224B1 (fr) Produits pharmaceutiques pour l'imagerie de troubles angiogenes
AU2007201609A1 (en) Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
US20020122768A1 (en) Stable radiopharmaceutical compositions and methods for preparation thereof
WO2001097860A2 (fr) Produits pharmaceutiques pour l'imagerie de troubles angiogeniques
US6524553B2 (en) Quinolone vitronectin receptor antagonist pharmaceuticals
WO2001097861A2 (fr) Agents pharmaceutiques antagonistes du recepteur de la vitronectine destines a etre utilises dans une therapie combinee
CA2349333A1 (fr) Medicaments antagonistes du recepteur de la vitronectine
US6548663B1 (en) Benzodiazepine vitronectin receptor antagonist pharmaceuticals
US7090828B2 (en) Vitronectin receptor antagonist pharmaceuticals
US6511649B1 (en) Vitronectin receptor antagonist pharmaceuticals
NZ522925A (en) Vitronectin receptor antagonist pharmaceuticals for use in combination therapy
AU2002243238A1 (en) Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
MXPA00009574A (en) Pharmaceuticals for the imaging of angiogenic disorders
CZ20003353A3 (cs) Farmaceutické sloučeniny pro zobrazování poruch angiogeneze

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2002 503343

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2413328

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001946697

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001946697

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001946697

Country of ref document: EP